Supported by

Diamond sponsors

Platinum sponsor

Silver sponsor

Part of

Official PR agency

Overview

“Enough time has been wasted issuing warnings about antibiotic resistance. The moment has come to do something about it” The Economist

The world is facing an imminent crisis of antimicrobial resistance (AMR). A growing range of disease-causing bacteria are proving difficult to treat; some are no longer treatable, even with the last line of antibiotic defences. In a classic case of market failure, ageing antibiotics that are increasingly less effective are not being replaced by new ones. Meanwhile, resistance is accelerating through the misuse and abuse of antibiotics—in humans, animals and the environment.

The Antimicrobial Resistance Summit asks why the global call to action on such a critical public good is now sputtering, and how renewed energy and momentum might be unlocked in the global fight against AMR. We ask how new voices can help broaden the AMR cause—from responsible investment and retailing to environmental groups and a wider universe of advocates. We ask for action.

How can surveillance of the supply chain be improved to stop substandard medicines reaching the market?

There are currently few licensed vaccines for the bacteria that are considered urgent AMR threats. How can we change this?

How can the transition from industry’s bottom-line reliance on overselling antibiotics be managed?

Message from Tom Standage, co-chair, AMR Summit

Join organisations registered to attend the 2019 event such as:

Access to Medicine Foundation
ACS DOBFAR S.p.A.
AHDB
ALK-Abello Ltd
AMR Centre
AMR Insights
Association of Clinical Research Organizations (ACRO)
Beaumont Hospital and Royal College of Surgeons in Ireland
BioVersys AG
British Poultry Council
British Society for Antimicrobial Chemotherapy
Brunswick
Bugworks Research Inc
CARB-X
Centers for Disease Control and Prevention
Centre for Genomic Pathogen Surveillance, Wellcome Sanger Institute, UK
Centre for Innovation Excellence in Livestock
Chatham House
Community for Open Acess Antimicrobial Discovery
Department of Health and Social Care
Division of Infection and Pathway Medicine, University of Edinburgh

MedTech Europe
The Bureau of Investigative Journalism
The European Bank for Reconstruction & Development
The Pew Charitable Trusts
The Pharma Letter
UNDP
University of Cambridge
University of Dundee
University of Ibadan
University of Liverpool
University of Nottingham
University of Oxford
Wellcome Trust
Willis Towers Watson
World AMR Congress
World Economic Forum
World Health Organisation
World Vaccine Congress
AND MANY MORE..

Speakers

Sally Davies

Chief medical officer and chief medical advisor, Government of the United Kingdom

Sally Davies

Chief medical officer and chief medical advisor, Government of the United Kingdom

Dame Sally is the Chief Medical Officer for England (CMO) and Chief Medical Advisor to the UK Government. Dame Sally founded the National Institute for Health Research (NIHR) and is a Non-Executive Director of Genomics England Ltd. She was a member of the WHO Executive Board and the Strategic and Technical Advisory Group on Antimicrobial Resistance (AMR). Dame Sally received her DBE in 2009, and is an elected Fellow of the Royal Society, Fellow of the Academy of Medical Sciences, UK, and a member of the National Academy of Medicine, USA. She was appointed co-convener of the UN Inter-Agency Co-ordination Group on AMR, set up in response to the UNGA 2016 declaration. Dame Sally first became captivated by AMR when she published her 2011 annual report on infectious diseases, highlighting the increasing threat of AMR and calling for global action to address key areas including stewardship, monitoring and surveillance, and antibiotic development.

Christopher Fearne

Minister for health, Malta

Christopher Fearne

Minister for health, Malta

Christopher Fearne was appointed minister for health after holding the position of parliamentary secretary for health since April 2014. In June 2017 he was re-appointed minister for health following the general elections and in July 2017 he was elected deputy prime minister following the Malta Labour Party’s extraordinary general council. Prior to this, Mr Fearne worked as a consultant paediatric surgeon and clinical chairman at Mater Dei Hospital. He is a member of parliament for the ruling Labour Party and was the chairman of the Foreign and European Affairs Committee at the Maltese House of Representatives.

Hon. Fearne has worked as a doctor and surgeon for over 30 years. He received his formal education at St. Aloysius College and at the University of Malta graduating in Medicine and Surgery in 1987, becoming a Fellow of The Royal College of Surgeons of Edinburgh. He worked and studied in a number of children’s hospitals in England, including the Great Ormond Street Hospital in London. He also lectures students of medicine at the University of Malta.

Marc Sprenger

Marc Sprenger

Marc Sprenger is director of the Antimicrobial Resistance Secretariat at the World Health Organisation in Geneva, a position he has held since September 2015. He is responsible for the co-ordination and implementation of the Global Action Plan on AMR. From 2010 until 2015, Mr Sprenger served as director of the European Centre for Disease Prevention and Control and from 2003 until 2010 was director general of the Dutch National Institute for Public Health and the Environment (RIVM). From 1999 to 2003, he was director of health of the Dutch National Healthcare Insurance Board providing guidance on healthcare system and insurance issues, including reimbursement of new pharmaceuticals. As head of the Centre for Infectious Disease Epidemiology, RIVM, from 1993 to 1999, Mr Sprenger established a new centre of national coordination of infectious disease epidemiology and initiated the European Antimicrobial Resistance Surveillance System.

Martin Seychell

Deputy director-general, Directorate-General for Health and Food Safety, European Commission

Martin Seychell

Deputy director-general, Directorate-General for Health and Food Safety, European Commission

A graduate in chemistry and pharmaceutical technology, Martin Seychell specialized in Chemical analysis. He has held important positions on several government boards and commissions in Malta, including the Food Safety Commission and the Pesticides Board. Martin Seychell occupied the post of Head of Directorate at the Malta Standards Authority between 2001 and 2006. He has been responsible for the implementation of a number of EU directives in the areas of risk assessment, food safety, chemicals and cosmetic products legislation, and has actively participated in negotiations on major technical proposals such as the new chemicals legislation, REACH, and in screening processes in the areas of free movement of goods, environment and agriculture during the process leading to Malta's accession to the EU. He held the post of Director of Environment in Malta between 2006 and 2011. As Director, he was responsible for a broad range of functions arising from the Maltese Environment Protection Act. He was appointed Deputy Director General for Health and Consumers at the European Commission in March 2011. Responsible for directorates dealing with Consumer affairs, Public health and Health systems and products (SANCO). 2014 - to date: Deputy Director-General for Health in the Health and Food Safety Directorate-General (SANTE).

Mandeep Dhaliwal

Director, HIV, health and development team, UNDP

Mandeep Dhaliwal

Director, HIV, health and development team, UNDP

MandeepDhaliwal is the director of UNDP’s HIV, Health and Development Group, Bureau of Policy and Programme Support. Ms Dhaliwal brings to the organisation over 20 years of experience working on multi-sectoral HIV and health responses and evidence-based policy and programming in low and middle-income countries. Ms. Dhaliwal joined UNDP in 2008 and was the architect of the Global Commission on HIV and the Law and led the secretariat for the United Nations Secretary-General’s High-Level Panel on Access to Medicine. Prior to joining UNDP, she was a senior adviser to the Dutch Royal Tropical Institute’s Special Programme on HIV/ AIDS. From 2000 to 2006, Ms. Dhaliwal worked for the International HIV/AIDS Alliance’s Policy, Research and Good Practice Team in the United Kingdom where she focused on issues of HIV care and treatment in developing countries. She was instrumental in expanding the International HIV/AIDS Alliance's technical support and policy work on issues of HIV care, treatment and support in Africa, Asia, Eastern Europe and Latin America. From 1993 to 2000, she worked on HIV and human rights issues in India, including as the founding Coordinator of the Lawyers Collective HIV/AIDS Unit, a leading human rights organization, establishing the Unit's legal aid, public interest litigation, legal literacy and policy/advocacy work.

Manica Balasegaram

Executive director, GARDP

Manica Balasegaram

Executive director, GARDP

Manica Balasegaram trained as a medical doctor at the University of Nottingham, UK from where he started his career in internal and emergency medicine. From 2001, he worked as a doctor and researcher in several countries in sub-Saharan Africa and South Asia and gained important experience in emergency medicine during humanitarian interventions, including with Doctors Without Borders (MSF).

At the end of 2007, he joined the Drugs for Neglected Diseases initiative (DNDi) as Head of the Leishmaniasis Clinical Program, a position he held for four years before returning to MSF as Executive Director of their Access to Essential Medicines Campaign in Geneva. In June 2016, he was appointed Director of GARDP and its Executive Director in July 2018.

Mr Balasegaram is currently a member of the Board of Directors of the Medicines Patent Pool (MPP) and the Scientific Advisory Board of FIND, two Geneva-based organizations. He has also been a lecturer since 2013 at the University of Geneva for a Diploma and Master of Advanced Studies (MAS) program in clinical research and development.

An expert in global health and infectious diseases, Mr Balasegaram is also recognized for his international work on health policies and access to medicines. He also has experience in clinical trials and drug development as a lead investigator and in project management.

Allan Coukell

Senior director, health programs, The Pew Charitable Trusts

Allan Coukell

Senior director, health programs, The Pew Charitable Trusts

Allan directs health work at The Pew Charitable Trusts, a nonprofit research and policy organization, overseeing initiatives related to antimicrobial resistance, substance use prevention and treatment, health IT, food safety, drug innovation, healthcare products and population health. Prior to joining Pew, he practised as a clinical pharmacist in oncology at the Victoria Hospital in London, Ontario, and served as a senior medical writer with the journal publisher Adis International Ltd. He also worked as a health and science reporter for WBUR, Boston’s National Public Radio news station, and at Radio New Zealand. He serves on the board of the Reagan Udall Foundation for the Food and Drug Administration. He is a graduate of the University of Manitoba and completed his hospital pharmacy residency at the Winnipeg Health Sciences Centre.

Maryn McKenna

Journalist and author, "Plucked! The truth about chicken"

Maryn McKenna

Journalist and author, "Plucked! The truth about chicken"

Maryn McKenna is an independent journalist who specialises in public health, global health and food policy. She is a columnist for WIRED, a senior fellow at the Center for the Study of Human Health at Emory University, and the author of the 2017 book PLUCKED (titled BIG CHICKEN in the United States), which received the 2018 Science in Society Award and was named a best book of 2017 by Amazon, Smithsonian, Science News, Wired, Civil Eats, and other publications. Her earlier, award-winning books are Superbug and Beating Back the Devil. She is one of the stars of the 2014 documentary Resistance, and her 2015 TED Talk, "What do we do when antibiotics don't work any more?" has been viewed 1.7 million times and translated into 34 languages. She writes for The New York Times Magazine, National Geographic, Mother Jones, Newsweek, NPR, Smithsonian, Scientific American, Slate, The Atlantic, Nature, and The Guardian, among many other publications. She was a 2018 Poynter Fellow in Journalism at Yale University and received the 2019 McGovern Award from the American Medical Writing Association, the 2014 Leadership Award from the Alliance for the Prudent Use of Antibiotics and the 2013 Byron H. Waksman Award for Excellence in the Public Communication of Life Sciences.

Timothy Jinks

Head, Drug Resistant Infections, Wellcome Trust

Timothy Jinks

Head, Drug Resistant Infections, Wellcome Trust

Timothy Jinks is the Head of the Drug Resistant Infections Priority Program leading Wellcome Trust’s strategic plan to address antimicrobial resistance. In his preceding role in Wellcome’s Innovations Division, he was responsible for a portfolio of over a dozen early stage product development projects covering therapeutics, diagnostic and devices spanning across therapeutic areas such as infectious diseases and oncology. He also serves on the Longitude Prize Committee, as Wellcome’s representative on the board of the Global R&D Innovation Hub and as Non-Executive Director of ReViral Ltd. Prior to joining the Trust in 2012 he has over a decade of industry experience in drug development, most recently as a consultant providing business development, licensing and commercial research services.

Lucica Ditiu

Executive director, Stop TB Partnership

Lucica Ditiu

Executive director, Stop TB Partnership

Lucica Ditiu is a Romanian physician and public health expert who has devoted her career to helping and supporting people affected by TB, especially those most vulnerable, most stigmatised and living in impoverished communities. Lucica Ditiu has led the Stop TB Partnership for the last 7 years. Under her leadership, the organisation has gained a clear identity and evolved into a lean, innovative and progressive team that represents one of the strongest advocacy voices on global health and tuberculosis, providing support - financial as well as TB medicines and diagnostics – for a TB response towards a world without TB. A strong believer in innovation, flexibility and change, Dr. Ditiu is relentless in pushing for the inclusion of all people affected by TB, with an ambitious agenda of transparency and accountability that continuously challenges the status quo.

Dr. Ditiu is a specialist in lung diseases and began practicing medicine in 1992 in Romania. She started her international career with the WHO in January 2000 as a medical officer for TB in Albania, Kosovo and Macedonia within the disaster and preparedness unit. She has worked for the past 18 years in the WHO and UN system at every level: national, sub regional, regional and global, and attributes her experience and expertise to delivering results while navigating all sorts of difficulties.

Clare Chandler

Director, antimicrobial resistance centre, London School of Hygiene and Tropical Medicine

Clare Chandler

Director, antimicrobial resistance centre, London School of Hygiene and Tropical Medicine

Clare Chandler is an associate professor in Medical Anthropology and director of the Antimicrobial Resistance Centre at the London School of Hygiene and Tropical Medicine. Ms Chandler has spent the past decade and a half researching how people use medicines and how health care is enacted across different low and middle income country settings. She leads a large research group to explore the ways societies around the globe have become reliant on antimicrobial medicines not only for treatment of illnesses but in anticipation of infections in humans, animals and in crops, and how this relates to wider economic and political imperatives. Her projects include the Anti-Microbials in Society (AMIS) Hub, an online resource of high quality social research on AMR. Clare provides technical advice about behavioural aspects of global health, for example on malaria, Ebola, and antimicrobial resistance, to various governmental and multi-lateral agencies.

Vanessa Candeias

Head, shaping the future of health and healthcare, World Economic Forum

Vanessa Candeias

Head, shaping the future of health and healthcare, World Economic Forum

Trained as a nutritionist, Faculty of Nutrition and Food Sciences, Porto University; Master’s in Public Health, London School of Hygiene and Tropical Medicine. Formerly: worked at national level on developing and implementing health promotion policies with the Ministry of Health in Portugal and the Institute of Preventive Medicine of the University of Lisbon; worked with the World Health Organization Headquarters on global guidelines and policy development for noncommunicable diseases. Currently, Head of System Initiative on Shaping the Future of Health and Healthcare and Member of the Executive Committee, World Economic Forum. The System Initiative on Shaping the Future of Health and Healthcare provides a dynamic platform for leading businesses, governments, civil society organizations and world class experts to shape the global health agenda; co-design and accelerate the implementation of collaborative approaches that transform the health ecosystem – across prevention, diagnosis, treatment, cure and maintenance of health; and ultimately enables populations to live healthier lives and have access to the care they need when they need it.

Kevin Outterson

Executive director and principal investigator, CARB-X

Kevin Outterson

Executive director and principal investigator, CARB-X

Kevin Outterson teaches health care law at Boston University, where he co-directs the Health Law Program. He serves as the executive director and principal investigator for CARB-X, a $540M international public-private partnership to accelerate global antibacterial innovation. Key partners in CARB-X include the US Government (BARDA & NIAID), the Wellcome Trust, the UK Government (GAMRIF, DHSC), the German Federal Ministry of Education and Research, and the Bill & Melinda Gates Foundation.

His research work focuses on the law and economics of antimicrobial resistance. Mr Outterson was a founding member of the Antimicrobial Resistance Working Group at the CDC. He was a senior consultant on the Eastern Research Group study on antibiotic markets for FDA/HHS. Starting in October 2014, he joined DRIVE-AB, a three-year €9 million project on antibiotic business models sponsored by the European Union’s Innovative Medicines Initiative. Professor Outterson also serves on the Advisory Panel for the Longitude Prize for an inexpensive rapid point-of-care antibiotic diagnostic. Professor Outterson was given the 2015 Leadership Award by the Alliance for the Prudent Use of Antibiotics for his research and advocacy work. He has testified before Congress, Parliamentary working groups, WHO, and several state legislatures.

Danuta Cichocka

Chief executive, Resistell

Danuta Cichocka

Chief executive, Resistell

Danuta Cichocka is a co-founder, chief executive and a chairperson of the Board of Directors at Resistell AG, the Swiss Federal Institutes of Technology (EPFL) spin-off developing fast and simple nano-motion based alternative to culture-based antibiogram. The company’s mission is to provide the physicians with the diagnostic tool that will enable them to choose the most efficient but also most narrow-spectrum antibiotic for the patient.

She is a microbiologist by training. She completed the Ph.D. at the UFZ Leipzig in 2008, followed by a post-doc at the KU Leuven, and a senior researcher position at FHNW in Basel (2012-2017). She has experience in research management and biotechnology policy development at a European level, gained at European Commission in Brussels (2009-2012). In 2016 she completed the Executive MBA program at the EPFL and obtained a Certificate of Advanced Studies (CAS) in Management of Biotech, Medtech & Pharma Ventures. At the beginning of 2017, Danuta initiated the collaboration with EPFL Laboratory of Physics of Living Matter on the commercialisation of nano-motion based technology for phenotypic antibiotic susceptibility testing, which resulted in the incorporation of the start-up in 2018.

Jayasree K. Iyer

Executive director, Access to Medicine Foundation

Jayasree K. Iyer

Executive director, Access to Medicine Foundation

Jayasree K. Iyer leads the strategic direction and stakeholder engagement of the Access to Medicine Foundation. She directs the research programmes for the Antimicrobial Resistance Benchmark, the Access to Medicine Index, the Access to Vaccines Index and specific studies into priority health topics.
To stimulate positive change within the pharmaceutical industry, Jayasree often speaks publicly on access-to-medicine matters on platforms hosted by international, governmental and non-governmental organisations, including the UN and WHO. In this capacity, she also engages with key pharmaceutical industry investors to support their engagement activities with pharma companies. She often refers to the Access to Medicine Index as a “book of solutions” for pharmaceutical companies working to improve their access footprints. Jayasree holds various postgraduate degrees (Masters and PhD) from Singapore and the John Hopkins School of Hygiene and Public Health. She has written many technical and research reports, book chapters and reviews, along with strategy papers for medicines for developing countries and solutions for neglected tropical diseases.
Before joining the Foundation, Jayasree spent four years managing a portfolio of more than 25 public private partnerships between the Dutch government and the pharmaceutical industry, totalling a research budget of €150 million. These partnerships addressed cancer, immunology and neglected diseases. She has worked for various non-government organisations, academic institutions and was part of the founding team of a diagnostic service company in the US.

Anand Anandkumar

Chief executive and managing director, Bugworks

Anand Anandkumar

Chief executive and managing director, Bugworks

Anand Anandkumar is co-founder and chief executive of Bugworks, a leading pharma start-up, one of a handful of companies working on developing novel classes of antibiotics to tackle the global problem posed by multi-drug resistant bacterial superbugs. The company’s lead asset, which is in preclinical development, is a novel dual target inhibitor with excellent potency against the entire list of WHO critical, high and medium threat pathogens. The company has won many national and international innovation awards including the best start-up in India (2015), Economic Times Top Innovator award (2017), first company outside north America and Europe to win the coveted CARB-X grant, and has been featured in the CB-InSights 2019 list of top 36 global start-ups. Bugworks has prominently featured on leading global platforms including the BBC, Wellcome Trust, UNCTAD, CDC and Forbes. Mr Anandkumar was previously co-founder and managing director, Cellworks, a company specialising in personalised oncotherapy, using mathematical modelling frameworks. He is also the co-founder of the India semiconductor association (IESA), member of executive committee of India Biotech association (ABLE), member of Eta-Kappa-Nu and Tau-Beta-Pi International Engineering honors societies, and most recently elected to the board of the AMR Industry alliance.

Adrian Thomas

Vice-president, global public health, Johnson & Johnson

Adrian Thomas

Vice-president, global public health, Johnson & Johnson

Adrian Thomas is the vice-president, Global Access, Programs & Policy, within the Johnson & Johnson Global Public Health organisation. Adrian has a special interest in the fields of public health, commercial and market access strategy, and pharmaceutical policy. He also held numerous roles in market access, including Global Head Health Economics & Market Access Medical Devices and Global Head of Market Access for Janssen, the pharmaceutical companies of Johnson & Johnson. He has also held roles in risk management and drug safety, including Global Head of Benefit Risk Management and Chief Safety Office for Janssen.

Prior to joining J&J, Adrian held roles in regional medical affairs, drug development and product management for Schering-Plough and Eli Lilly. He is a clinical pharmacologist and vascular physician by training with experience in clinical trials design and methodology.

Adrian is a Fellow of the Royal Australasian College of Physicians and the College of Medical Administrator’s. He received his Bachelor of Medicine and Bachelor of Surgery degrees from the University of Melbourne in Australia.

Keiji Fukuda

Director and clinical professor, school of public health, The University of Hong Kong

Keiji Fukuda

Director and clinical professor, school of public health, The University of Hong Kong

Keiji Fukuda is the director and a clinical professor at The University of Hong Kong School of Public Health. He previously worked at the World Health Organisation (WHO) in several capacities including assistant director-general (ADG) and special representative of the director-general for antimicrobial resistance; ADG for the health security and environment cluster; and director of the Global Influenza Programme. Before that, he worked at the U.S. Centers for Disease Control and Prevention (CDC) as the epidemiology section chief, influenza branch and as a medical epidemiologist in the viral exanthems and herpesvirus branch, National Center for Infectious Diseases. Mr Fukuda has been a global public health leader in many areas including health security; emerging infectious diseases including seasonal, avian and pandemic influenza, SARS, MERS and Ebola; antimicrobial resistance; development of the Pandemic Influenza Preparedness Framework; implementation of the International Health Regulations; food safety; and chronic fatigue syndrome. He has considerable experience in epidemiological research and field investigations, media communications and international diplomatic negotiations including those held to establish a historic heads of state level meeting on antimicrobial resistance at the United Nations in 2016.

Oliver van Hecke

Oliver van Hecke

Oliver van Hecke is a clinical lecturer at the Department of Primary Care Health Sciences, University of Oxford. His PhD focussed on the impact of AMR in the community and the implications for future intervention. His research interests are in optimising antibiotic use for common infections in the community and antibiotic resistance. This stems from his work as a generalist practising in the NHS with first-hand experience of the difficulties that GP’s encounter. He is also a key member of the newly established National Institute for Health Research (NIHR) Community Healthcare MIC (MedTech and In vitro diagnostics Co-operative) based at Oxford, which aims to speed up the development, evaluation, and use of diagnostic tests. As part of the Infections research team at the University of Oxford, he is keen to foster local, national and international collaborations especially in resource-poor settings.

David Heymann

Head, centre for global health security, Chatham House

David Heymann

Head, centre for global health security, Chatham House

David Heymann is professor of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine and head of the Centre on Global Health Security at Chatham House, London. From 2012 to March 2017 he was chairman of Public Health England, UK, and prior to that was assistant director of the World Health Organisation, and executive director of the WHO Communicable Diseases Cluster, during which he headed the global response to SARS. Before WHO, Mr Heymann worked for 13 years as a medical epidemiologist in sub-Saharan Africa, on assignment from the US CDC, where he participated in the response to the first, second and third outbreaks of Ebola in DRC. Prior to joining CDC, he worked in India as a medical epidemiologist in the WHO smallpox eradication programme. He is an elected fellow of the Institute of Medicine (US) and the Academy of Medical Sciences (UK). He is a recipient of the Heinz Award on the Human Condition, which has provided funding for the establishment of an on-going mentorship programme at the International Association of Public Health Institutes (IANPHI). Heymann has over 200 peer reviewed publications, commentaries and book chapters, and is the editor of the Control of Communicable Diseases Manual, a global reference for public health and health protection. In 2009 he was appointed an honorary Commander of the Most Excellent Order of the British Empire (CBE) for service to global public health.

Nobuko Ichikawa

Senior environmental advisor, The European Bank for Reconstruction and Development (EBRD)

Nobuko Ichikawa

Senior environmental advisor, The European Bank for Reconstruction and Development (EBRD)

Nobuko Ichikawa is a senior environmental advisor in the Environment Department of the European Bank for Reconstruction and Development (EBRD) in London, U.K. Since the UN resolution to combat the proliferation of AMR was issued in September 2016, she has been working on AMR initiatives to effectively recognise AMR risks and take adequate mitigation measure at the project level as well through the policy dialogue. She has been working in EBRD since 1996 and prior to EBRD, she had worked in the World Bank in Washington D.C. from 1991 to 1996. Her work in EBRD focuses on environmental due diligence for the health care services, PPP hospital facilities, property and tourism, information technologies/telecommunication, urban redevelopment and cultural heritage and social inclusion in EBRD countries of operations. With the World Bank, she worked on industrial pollution prevention policy work in Vietnam, Thailand and Malaysia. She obtained a master in urban studies and city planning in MIT in Cambridge, M.A., master in Hosei University and bachelor in Chuo University in Tokyo. Nobuko has been working and living in Thailand, the U.S. and U.K for the last 30 years.

Zamin Iqbal

Research group leader, European Bioinformatics Institute

Zamin Iqbal

Research group leader, European Bioinformatics Institute

ZaminIqbal leads a research team at the European Bioinformatics Institute EBI), working on fundamental algorithms for studying pathogen DNA,

And their application in the clinic. His team have developed fast software that can spot drug-resistance in TB in minutes on a laptop , and then showed that comprehensive TB tests could be done in just 12 hours (down from 2 weeks) going from sputum-sample to diagnosis on a handheld device. He is co-holder of a Longitude Prize Discovery award to trial handheld TB testing in Vietnam and India. He is working with collaborators in Madagascar and Peru to develop a free global diagnostic and monitoring service for TB (Mykrobe Atlas). In addition, his team have developed the first global DNA search engine, indexing all bacterial and viral DNA that has ever been sequenced, and used this to show that mobile DNA called “plasmids” which carry drug resistance are more widely spread across the tree of life. At EBI, he is building this as a live service, allowing real-time search of all global microbial DNA.

He has been external consultant for CDC Atlanta, and is on the genome sequencing steering committee for Public Health England.

Jean Patel

Jean Patel

Jean Patel is a clinical microbiologist with specific expertise in the laboratory detection of antimicrobial resistance. At CDC, Jean leads implementation of CDC’s Antibiotic Resistance Laboratory Network and the CDC and FDA Antibiotic Resistance Isolate Bank. Ms Patel has experience leading the CDC Antimicrobial Resistance Laboratory and prior to CDC worked as the assistant director of the Clinical Microbiology Laboratory of the Hospital of the University of Pennsylvania. Ms Patel has served as chair and vice-chair of the Clinical and Laboratory Standards Institute Subcommittee for Antimicrobial Susceptibility Testing and works with the World Health Organisation to develop technical guidance for detecting resistance and strengthening global surveillance of antimicrobial resistance.

Kristina Lagerstedt

Founder and chief executive, 1928 Diagnostics

Kristina Lagerstedt

Founder and chief executive, 1928 Diagnostics

Kristina Lagerstedt is a Swedish tech and healthcare entrepreneur and scientist who founded the digital health company 1928 Diagnostics and serves as its chief executive. 1928 Diagnostics offers a DNA analytics platform to clinical and public health laboratories globally for intelligent infection control and diagnostics with the mission to save the power of antibiotics. 1928 Diagnostics was announced a Technology Pioneer Champion by the World Economic Forum in 2018 and Ms Lagerstedt is a member of Digital Leaders of Europe. Ms Lagerstedt has also worked as a clinical cancer scientist focusing on identifying and commercialising molecular biomarkers for detecting and guiding the treatment of cancer.

Wilson Mok

Head of policy, Gavi, The Vaccine Alliance

Wilson Mok

Head of policy, Gavi, The Vaccine Alliance

Wilson Mok serves as the head of policy at Gavi, the Vaccine Alliance. In this role he oversees Gavi’s vaccine investment decision-making and programmatic policies. Prior to joining Gavi in 2013, Wilson served as a strategy consultant at the Bill & Melinda Gates Foundation, focusing on antiretroviral-based HIV prevention. He was also previously a management consultant with McKinsey & Co based in New York, advising healthcare companies and public sector clients. Wilson holds degrees in chemical engineering from the University of California at Berkeley and the Massachusetts Institute of Technology.

Philip Howard

Philip Howard

Philip Howard is Consultant Pharmacist in Antimicrobials at the Leeds Teaching Hospitals NHS Trust, National AMR Project Lead at NHS-Improvement and Honorary Visiting Professor at Leeds University. He is a spokesman for the Royal Pharmaceutical Society on Antimicrobials, and for the Antibiotic-Action and British Society of Antimicrobial Chemotherapy charities. He was a member of the Dept of Health ARHAI Antimicrobial Stewardship Group that produced the original Start Smart then Focus Antimicrobial Stewardship Guidelines, and the HPA Primary Care Unit which helped produce the RCGP TARGET guidance on Antimicrobial Stewardship in Primary Care. His research interests include Antimicrobial Stewardship, and led the first global hospital Antimicrobial Stewardship survey. He has been involved in AMS education and training across the world. He’s won the GHP/GSK/UKCPA Clinical Leadership Award and the UKCPA Lifetime Achievement Award

Iruka N Okeke

Professor, University of Ibadan, Nigeria

Iruka N Okeke

Professor, University of Ibadan, Nigeria

Iruka N Okeke is a member of Nigeria’s Technical Working Group on Antimicrobial Resistance and is instituting genomic surveillance of antimicrobial resistance as part of a collaborative National Institute for Health-supported Global Health Research Unit. Ms Okeke is a professor of pharmaceutical microbiology at the University of Ibadan, Nigeria and an African research leader supported by the UK Medical Research Council MRC and Department for International Development. Her research group investigates the mechanisms bacteria use to colonise humans, cause disease and gain drug resistance. She also studies laboratory practice in Africa.

Ms Okeke is a fellow of the Nigerian and the African Academies of Science. She is extensively published in the fields of microbiology, genetics and science and technology studies and is the editor-in-chief of the African Journal of Laboratory Medicine. Iruka is on the Wellcome Trust’s Surveillance and Epidemiology of Drug Resistant Infections Consortium (SEDRIC) advisory board and currently serves as a drug resistance consultant to the Nigeria Centre for Disease Control (CDC), WHO and other organisations.

Mark Pearson

Deputy director, employment, labour and social affairs, OECD

Mark Pearson

Deputy director, employment, labour and social affairs, OECD

Mark Pearson is deputy director for Employment, Labour and Social Affairs (ELS) at the OECD. Mr Pearson works with the director to provide leadership in the co-ordination and management of the activities of ELS and ensure that it is at the forefront of the international health, social and employment agenda. Mr. Pearson joined the OECD in 1992, initially working on tax issues. He then moved to ELS, becoming the head of the Social Policy Division from 2000-2008. In 2009 he became head of the Health Division where the central focus of work was on how to deliver health care with greater efficiency. As deputy director since 2015, he has overseen the work of the organisation on topics such as antimicrobial resistance, diversity, inequality and pharmaceutical pricing.

David Salisbury

Former director of immunisation, Department of Health, London

David Salisbury

Former director of immunisation, Department of Health, London

David Salisbury was made a Companion of the Order of the Bath in the Queen’s Birthday Honours, 2001, for his services to immunisation. Mr Salisbury was director of immunisation at the Department of Health, London, until 2014; he was responsible for the UK national immunisation programme. During that time he introduced numerous new vaccines, dealt with the MMR autism crisis and advised other governments and international organisations.
He is chair of the board of the Jenner Vaccine Foundation and was inaugural president of the International Association of Immunisation Managers. Mr Salisbury continues to work extensively with the WHO on the Global Programme for Vaccines. He was the chair of the WHO Strategic Advisory Group of Experts on Vaccines from 2005 to 2010. He is chair of the Global Commission for Certification of Poliomyelitis Eradication and chair of the European Region Certification Commission for Poliomyelitis Eradication. He serves on advisory boards for four EC-funded vaccine research projects. He has also had extensive experience in Global Health Security having co-chaired a G7 working group on pandemic influenza for nine years.

Mr Salisbury trained as a paediatrician at Oxford and at the Hospital for Sick Children, Great Ormond Street, London. He is a fellow of the Royal College of Physicians, fellow of the Royal College of Paediatrics and Child Health, fellow of the Faculty of Public Health, and fellow of the Academy of Medical Sciences. He has an honorary chair at Imperial College, London and is an associate fellow at the Centre on Global Health Security, Royal Institute of International Affairs, Chatham House, London.
Mr Salisbury has written around 100 publications on immunisation and paediatric topics.

Jaideep Gogtay

Global chief medical officer, Cipla

Jaideep Gogtay

Global chief medical officer, Cipla

Jaideep Gogtay is the global chief medical officer at Cipla and has been associated with the organisation for nearly 25 years now. At Cipla, he has been closely involved in the development and introduction of several drugs in
various therapeutic fields, particularly in HIV/AIDS, infectious diseases and respiratory diseases. He has worked on several clinical trials in the field of asthma, COPD and infectious diseases. He was a key member of the team which introduced several antiretroviral drugs for
the treatment of AIDS including the 1$ a day triple drug cocktail. Cipla has a large number of anti-infective drugs including antibiotics, anti-viral and anti-fungal which are available in a number of countries. As head of medical affairs, he was responsible for bringing back ‘old’ antibiotics such as Colistin which was reintroduced in India after over 50 years. One of the areas that Cipla continues to work is to update physicians on appropriate use of antibiotics and the current challenges of antimicrobial resistance, both in the community and in the hospital.
He was a member of the Association of Physicians of India (Guidelines 2005) on ‘Antiretroviral therapy’. He has 40 publications to his credit including chapters on Pharmacokinetics and Pharmacodynamics of antibiotics and has presented papers at over 50 conferences. He was
involved in setting up the Chest Research Foundation (CRF), now an independent research center dedicated to research in the field of respiratory medicine. He is a frequent presence in workshops on research methodology at academic institutions and at several national and
international forums.

Aleks Engel

Partner, Novo Holdings A/S

Aleks Engel

Partner, Novo Holdings A/S

Aleks Engel is a partner with Novo Holdings A/S based out of Copenhagen. He is also the director of the REPAIR Impact Fund, a $165m fund investing in early stage novel anti-microbial therapies targeting drug-resistant pathogens. Aleks joined Novo Holdings A/S in September 2014.

Prior to joining Novo Holdings, Aleks was employed as Vice President in Baxter International in Illinois and Shanghai, working with global M&A licensing, growth strategies, investment prioritization and go-to-market planning. Other previous employments include Pfizer Global Research and Development, and McKinsey & Company (all U.S.A.).

Aleks holds a Ph.D. in Biochemical Engineering (1999) and a M.Sc. in Chemical Engineering Practice (1995) from Massachusetts Institute of Technology.

Jesús Rueda Rodríguez

Director International Affairs, MedTech Europe

Jesús Rueda Rodríguez

Director International Affairs, MedTech Europe

Jesús heads the International Affairs team. He is involved in the work at the international level acting as representative to WHO, ISO and as liaison to other associations on all regulatory matters. Directly involved in the discussions on the revision and recast of the IVD Directive, he previously lead the regulatory debates that affect IVDs at EU level until 2016.

Harshika Sarbajna

Global head of anti-infectives, Sandoz

Harshika Sarbajna

Global head of anti-infectives, Sandoz

Harshika Sarbajna is the global head of anti-infectives for Sandoz, a Novartis Division. In this role, she is responsible for ensuring sustainable growth of the antibiotics portfolio at Sandoz, the largest provider of generic antibiotics globally, working closely with markets and various functions within Sandoz. In this role, she is also spearheading Sandoz & Novartis wide AMR Stewardship program, bringing together stakeholders both inside and outside the organisation. She previously served as the global head of strategy and operations of the Biosimilars business unit within Sandoz, and was part of the business leadership team. During Harshika’s tenure, she successfully led development and implementation of the commercial, portfolio and manufacturing strategy of the biosimilars business that delivered two successful biosimilar launches in Europe, and double-digit growth of in-market products across the globe.

Prior to Sandoz, Ms Sarbajna served as the head of business strategy for the biosimilars business at Dr. Reddy’s Lab, and drove growth across the portfolio in key markets including US, Asia, Latin America and Russia. Before joining Dr. Reddy’s, she led various executive-level advisory engagements on business and growth strategy for large Corporates and PE funds as principal consultant with The Parthenon Group.

Pol Vandenbroucke

Chief medical officer, Pfizer Hospital Business Unit

Pol Vandenbroucke

Chief medical officer, Pfizer Hospital Business Unit

Pol Vandenbroucke serves on the Board of BIO Ventures for Global Health, and of the American Federation for Aging Research; He is a member of the Advisory Board of the Steve Biko Centre for Bioethics, University of the Witwatersrand, Johannesburg, South Africa and a Fellow of the Faculty of Pharmaceutical Medicine of the Royal Colleges of Medicine of the United Kingdom. A frequent speaker on health, aging, diversity and policy issues, he is also a Visiting Senior Lecturer at King’s College and the Module Coordinator for Medical Affairs in the Medicines Development Certificate Program at IFAPP Academy and King’s College London. Mr Vandenbroucke’ s career has been dedicated to Clinical Development and Medical Affairs and has included stints in the U.S., Europe, Asia, and Latin America. Before his current position, he was Chief Development Officer for Pfizer Essential Health, Head of Medical Strategy for Pfizer Inc. and VP Medical Affairs of Pfizer’s Essential Health portfolio in North America. He previously also led the Clinical Development of all Pfizer compounds in Asia, Central/Eastern Europe, Latin America, and Africa-Middle East and of Pfizer’s Established Products globally. He was also responsible for developing compounds specifically for diseases of the developing world, such as malaria and river blindness.

Nina Grundmann

Senior manager, global health and economic policy, IFPMA

Nina Grundmann

Senior manager, global health and economic policy, IFPMA

Nina Grundmann joined the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) in June 2012. She leads IFPMA’s work on antimicrobial resistance and heads the secretariat of the AMR Industry Alliance, which represents more than 100 pharmaceutical companies. Nina has also worked on vaccine regulatory and programmatic policy and influenza vaccines. Nina holds a master’s degree in International Affairs from the French Institute of Political Studies and a post-graduate degree in Risk Management from HEC Business School in Paris. Prior to joining IFPMA, Nina worked at Sanofi Pasteur on vaccination policy and advocacy and for the Mérieux Foundation to help enhance research capabilities in developing countries.

Eliud Wandwalo

Senior disease co-ordinator for TB, The Global Fund

Eliud Wandwalo

Senior disease co-ordinator for TB, The Global Fund

Eliud joined the Global Fund in 2013. As the senior disease co-ordinator, he serves as the primary point for leadership and strategic guidance on TB, collaborating across the Global Fund secretariat and external partners to ensure Global Fund resources are strategically invested for impact. Before joining the Global Fund, Eliud worked with Management Sciences for Health (MSH) as regional principal technical advisor for TB supporting African countries. Prior to that Eliud worked with National TB Programme in Tanzania for over 10 years. Eliud completed his medical training from University of Dar Es Salaam, Tanzania and his master and PhD studies from Bergen University in Norway.

Adam Cunningham

Co-director, Bacterial Vaccines (BactiVac) Network

Adam Cunningham

Co-director, Bacterial Vaccines (BactiVac) Network

Adam Cunningham is professor of Functional Immunity at the University of Birmingham. He is Co-Director of the Bacterial Vaccines (BactiVac) Network. This Global Challenges Research Fund/Medical Research Council funded global network links and supports researchers from around the world to accelerate the development and use of vaccines against bacterial infections, particularly those of relevance to Low and Middle Income Countries. In addition to this role, Adam has an active research portfolio that focuses on how bacterial infections can harm us and how the immune system can protect us against infection, both naturally and after vaccination. Adam’s research on vaccines focuses on how we respond to vaccines, how we can improve the protection they offer and how we can make vaccines work more efficiently in those groups of people most vulnerable to infections.

Slavea Chankova

Healthcare correspondent, The Economist

Slavea Chankova

Healthcare correspondent, The Economist

Slavea Chankova is The Economist’s health-care correspondent. She was previously on the data journalism team and the Britain section, writing about health, gender, science and social policy trends. She joined The Economist in 2015. Before that she worked in international development and economic consulting. She is a graduate of Princeton University.

Charles Goddard

Editorial director, global initiatives, The Economist Group

Charles Goddard

Editorial director, global initiatives, The Economist Group

Charles Goddard leads the Economist Intelligence Unit’s editorial services in Asia-Pacific, including Corporate Network, a peer group for senior decision-makers of global businesses operating in the region. A journalist by background, he has worked across a range of publications and services at the Economist Intelligence Unit, including as author of the China Market Atlas series and director of its research divisions. A frequent traveller and speaker, he interacts regularly with business and government leaders across Asia. He is also executive director of The Economist’s World Ocean Summit, a global series of events on the sustainable use of our seas.

Tom Standage

Deputy editor, The Economist

Tom Standage

Deputy editor, The Economist

Tom Standage is the deputy editor of The Economist. He is also responsible for the newspaper's digital strategy and the development of new digital products, including Espresso and Economist Films. He is also the author of six history books, including Writing on the Wall (2013), A History of the World in 6 Glasses (2005) and The Victorian Internet (1998). He studied engineering and computing at Oxford University and has written for other publications including the New York Times, Daily Telegraph, Guardian and Wired, taking a particular interest in the internet's cultural and historical significance. He joined The Economist as science correspondent in 1998 and was subsequently appointed technology editor, business editor and digital editor.

Elizabeth Sukkar

Editor, Thought Leadership, The Economist Intelligence Unit

Elizabeth Sukkar

Editor, Thought Leadership, The Economist Intelligence Unit

Elizabeth is an editor in the Economist Intelligence Unit’s Thought Leadership team. She has been a journalist and editor for more than 15 years, covering healthcare policy, R&D and science for medical journals and UK newspapers, including the British Medical Journal and the Guardian. Before joining the EIU, she was the deputy news editor at the Royal Pharmaceutical Society, where she ran the news and analysis desk, and was often called to comment about healthcare issues on BBC radio. She also managed a team of international journalists when she was the world editor of Informa’s Scrip Intelligence, a global publication on pharmaceutical and healthcare policy, where she won the Informa Journalist of Year award. Before moving into journalism, Elizabeth worked as a pharmacist in community, hospital and health authority settings.

Agenda

Registration

8:45 AM

CHAIRMAN’S OPENING REMARKS

Charles Goddard

Editorial director, global initiatives, The Economist Group

Charles Goddard

Editorial director, global initiatives, The Economist Group

Charles Goddard leads the Economist Intelligence Unit’s editorial services in Asia-Pacific, including Corporate Network, a peer group for senior decision-makers of global businesses operating in the region. A journalist by background, he has worked across a range of publications and services at the Economist Intelligence Unit, including as author of the China Market Atlas series and director of its research divisions. A frequent traveller and speaker, he interacts regularly with business and government leaders across Asia. He is also executive director of The Economist’s World Ocean Summit, a global series of events on the sustainable use of our seas.

9:00 AM

Keynote interview with Dame Sally Davies

Sally Davies

Chief medical officer and chief medical advisor, Government of the United Kingdom

Sally Davies

Chief medical officer and chief medical advisor, Government of the United Kingdom

Dame Sally is the Chief Medical Officer for England (CMO) and Chief Medical Advisor to the UK Government. Dame Sally founded the National Institute for Health Research (NIHR) and is a Non-Executive Director of Genomics England Ltd. She was a member of the WHO Executive Board and the Strategic and Technical Advisory Group on Antimicrobial Resistance (AMR). Dame Sally received her DBE in 2009, and is an elected Fellow of the Royal Society, Fellow of the Academy of Medical Sciences, UK, and a member of the National Academy of Medicine, USA. She was appointed co-convener of the UN Inter-Agency Co-ordination Group on AMR, set up in response to the UNGA 2016 declaration. Dame Sally first became captivated by AMR when she published her 2011 annual report on infectious diseases, highlighting the increasing threat of AMR and calling for global action to address key areas including stewardship, monitoring and surveillance, and antibiotic development.

Charles Goddard

Editorial director, global initiatives, The Economist Group

Charles Goddard

Editorial director, global initiatives, The Economist Group

Charles Goddard leads the Economist Intelligence Unit’s editorial services in Asia-Pacific, including Corporate Network, a peer group for senior decision-makers of global businesses operating in the region. A journalist by background, he has worked across a range of publications and services at the Economist Intelligence Unit, including as author of the China Market Atlas series and director of its research divisions. A frequent traveller and speaker, he interacts regularly with business and government leaders across Asia. He is also executive director of The Economist’s World Ocean Summit, a global series of events on the sustainable use of our seas.

9:20 AM

Keynote panel: The global call to action

A persistent concern among those leading the charge against AMR is that the energy and momentum around the global call to action, so palpable following the UNGA special declaration in September 2016, are faltering and political will is fading. Where does the global call to action go from here?

How can campaigners translate rhetoric into action?

How can national health systems complement supranational incentives?

How can we avoid duplicating efforts?

David Heymann

Head, centre for global health security, Chatham House

David Heymann

Head, centre for global health security, Chatham House

David Heymann is professor of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine and head of the Centre on Global Health Security at Chatham House, London. From 2012 to March 2017 he was chairman of Public Health England, UK, and prior to that was assistant director of the World Health Organisation, and executive director of the WHO Communicable Diseases Cluster, during which he headed the global response to SARS. Before WHO, Mr Heymann worked for 13 years as a medical epidemiologist in sub-Saharan Africa, on assignment from the US CDC, where he participated in the response to the first, second and third outbreaks of Ebola in DRC. Prior to joining CDC, he worked in India as a medical epidemiologist in the WHO smallpox eradication programme. He is an elected fellow of the Institute of Medicine (US) and the Academy of Medical Sciences (UK). He is a recipient of the Heinz Award on the Human Condition, which has provided funding for the establishment of an on-going mentorship programme at the International Association of Public Health Institutes (IANPHI). Heymann has over 200 peer reviewed publications, commentaries and book chapters, and is the editor of the Control of Communicable Diseases Manual, a global reference for public health and health protection. In 2009 he was appointed an honorary Commander of the Most Excellent Order of the British Empire (CBE) for service to global public health.

Marc Sprenger

Marc Sprenger

Marc Sprenger is director of the Antimicrobial Resistance Secretariat at the World Health Organisation in Geneva, a position he has held since September 2015. He is responsible for the co-ordination and implementation of the Global Action Plan on AMR. From 2010 until 2015, Mr Sprenger served as director of the European Centre for Disease Prevention and Control and from 2003 until 2010 was director general of the Dutch National Institute for Public Health and the Environment (RIVM). From 1999 to 2003, he was director of health of the Dutch National Healthcare Insurance Board providing guidance on healthcare system and insurance issues, including reimbursement of new pharmaceuticals. As head of the Centre for Infectious Disease Epidemiology, RIVM, from 1993 to 1999, Mr Sprenger established a new centre of national coordination of infectious disease epidemiology and initiated the European Antimicrobial Resistance Surveillance System.

Jayasree K. Iyer

Executive director, Access to Medicine Foundation

Jayasree K. Iyer

Executive director, Access to Medicine Foundation

Jayasree K. Iyer leads the strategic direction and stakeholder engagement of the Access to Medicine Foundation. She directs the research programmes for the Antimicrobial Resistance Benchmark, the Access to Medicine Index, the Access to Vaccines Index and specific studies into priority health topics.
To stimulate positive change within the pharmaceutical industry, Jayasree often speaks publicly on access-to-medicine matters on platforms hosted by international, governmental and non-governmental organisations, including the UN and WHO. In this capacity, she also engages with key pharmaceutical industry investors to support their engagement activities with pharma companies. She often refers to the Access to Medicine Index as a “book of solutions” for pharmaceutical companies working to improve their access footprints. Jayasree holds various postgraduate degrees (Masters and PhD) from Singapore and the John Hopkins School of Hygiene and Public Health. She has written many technical and research reports, book chapters and reviews, along with strategy papers for medicines for developing countries and solutions for neglected tropical diseases.
Before joining the Foundation, Jayasree spent four years managing a portfolio of more than 25 public private partnerships between the Dutch government and the pharmaceutical industry, totalling a research budget of €150 million. These partnerships addressed cancer, immunology and neglected diseases. She has worked for various non-government organisations, academic institutions and was part of the founding team of a diagnostic service company in the US.

Timothy Jinks

Head, Drug Resistant Infections, Wellcome Trust

Timothy Jinks

Head, Drug Resistant Infections, Wellcome Trust

Timothy Jinks is the Head of the Drug Resistant Infections Priority Program leading Wellcome Trust’s strategic plan to address antimicrobial resistance. In his preceding role in Wellcome’s Innovations Division, he was responsible for a portfolio of over a dozen early stage product development projects covering therapeutics, diagnostic and devices spanning across therapeutic areas such as infectious diseases and oncology. He also serves on the Longitude Prize Committee, as Wellcome’s representative on the board of the Global R&D Innovation Hub and as Non-Executive Director of ReViral Ltd. Prior to joining the Trust in 2012 he has over a decade of industry experience in drug development, most recently as a consultant providing business development, licensing and commercial research services.

Charles Goddard

Editorial director, global initiatives, The Economist Group

Charles Goddard

Editorial director, global initiatives, The Economist Group

Charles Goddard leads the Economist Intelligence Unit’s editorial services in Asia-Pacific, including Corporate Network, a peer group for senior decision-makers of global businesses operating in the region. A journalist by background, he has worked across a range of publications and services at the Economist Intelligence Unit, including as author of the China Market Atlas series and director of its research divisions. A frequent traveller and speaker, he interacts regularly with business and government leaders across Asia. He is also executive director of The Economist’s World Ocean Summit, a global series of events on the sustainable use of our seas.

10:05 AM

Fireside chat

Maryn McKenna

Journalist and author, "Plucked! The truth about chicken"

Maryn McKenna

Journalist and author, "Plucked! The truth about chicken"

Maryn McKenna is an independent journalist who specialises in public health, global health and food policy. She is a columnist for WIRED, a senior fellow at the Center for the Study of Human Health at Emory University, and the author of the 2017 book PLUCKED (titled BIG CHICKEN in the United States), which received the 2018 Science in Society Award and was named a best book of 2017 by Amazon, Smithsonian, Science News, Wired, Civil Eats, and other publications. Her earlier, award-winning books are Superbug and Beating Back the Devil. She is one of the stars of the 2014 documentary Resistance, and her 2015 TED Talk, "What do we do when antibiotics don't work any more?" has been viewed 1.7 million times and translated into 34 languages. She writes for The New York Times Magazine, National Geographic, Mother Jones, Newsweek, NPR, Smithsonian, Scientific American, Slate, The Atlantic, Nature, and The Guardian, among many other publications. She was a 2018 Poynter Fellow in Journalism at Yale University and received the 2019 McGovern Award from the American Medical Writing Association, the 2014 Leadership Award from the Alliance for the Prudent Use of Antibiotics and the 2013 Byron H. Waksman Award for Excellence in the Public Communication of Life Sciences.

Tom Standage

Deputy editor, The Economist

Tom Standage

Deputy editor, The Economist

Tom Standage is the deputy editor of The Economist. He is also responsible for the newspaper's digital strategy and the development of new digital products, including Espresso and Economist Films. He is also the author of six history books, including Writing on the Wall (2013), A History of the World in 6 Glasses (2005) and The Victorian Internet (1998). He studied engineering and computing at Oxford University and has written for other publications including the New York Times, Daily Telegraph, Guardian and Wired, taking a particular interest in the internet's cultural and historical significance. He joined The Economist as science correspondent in 1998 and was subsequently appointed technology editor, business editor and digital editor.

10:20 AM

Panel: Better data, better knowledge?

New initiatives such as the Global Antimicrobial Resistance Surveillance System (GLASS) aim to gradually build a picture of resistant bugs across the world. We need a better picture as to how many people die from or survive AMR-related episodes, how concentrated resistant genes are in the environment, and what might be the most appropriate and affordable interventions. The paucity of data is especially acute in developing countries. How can “big data” enhance our understanding of the epidemiology of resistant organisms?

Jean Patel

Jean Patel

Jean Patel is a clinical microbiologist with specific expertise in the laboratory detection of antimicrobial resistance. At CDC, Jean leads implementation of CDC’s Antibiotic Resistance Laboratory Network and the CDC and FDA Antibiotic Resistance Isolate Bank. Ms Patel has experience leading the CDC Antimicrobial Resistance Laboratory and prior to CDC worked as the assistant director of the Clinical Microbiology Laboratory of the Hospital of the University of Pennsylvania. Ms Patel has served as chair and vice-chair of the Clinical and Laboratory Standards Institute Subcommittee for Antimicrobial Susceptibility Testing and works with the World Health Organisation to develop technical guidance for detecting resistance and strengthening global surveillance of antimicrobial resistance.

Zamin Iqbal

Research group leader, European Bioinformatics Institute

Zamin Iqbal

Research group leader, European Bioinformatics Institute

ZaminIqbal leads a research team at the European Bioinformatics Institute EBI), working on fundamental algorithms for studying pathogen DNA,

And their application in the clinic. His team have developed fast software that can spot drug-resistance in TB in minutes on a laptop , and then showed that comprehensive TB tests could be done in just 12 hours (down from 2 weeks) going from sputum-sample to diagnosis on a handheld device. He is co-holder of a Longitude Prize Discovery award to trial handheld TB testing in Vietnam and India. He is working with collaborators in Madagascar and Peru to develop a free global diagnostic and monitoring service for TB (Mykrobe Atlas). In addition, his team have developed the first global DNA search engine, indexing all bacterial and viral DNA that has ever been sequenced, and used this to show that mobile DNA called “plasmids” which carry drug resistance are more widely spread across the tree of life. At EBI, he is building this as a live service, allowing real-time search of all global microbial DNA.

He has been external consultant for CDC Atlanta, and is on the genome sequencing steering committee for Public Health England.

Allan Coukell

Senior director, health programs, The Pew Charitable Trusts

Allan Coukell

Senior director, health programs, The Pew Charitable Trusts

Allan directs health work at The Pew Charitable Trusts, a nonprofit research and policy organization, overseeing initiatives related to antimicrobial resistance, substance use prevention and treatment, health IT, food safety, drug innovation, healthcare products and population health. Prior to joining Pew, he practised as a clinical pharmacist in oncology at the Victoria Hospital in London, Ontario, and served as a senior medical writer with the journal publisher Adis International Ltd. He also worked as a health and science reporter for WBUR, Boston’s National Public Radio news station, and at Radio New Zealand. He serves on the board of the Reagan Udall Foundation for the Food and Drug Administration. He is a graduate of the University of Manitoba and completed his hospital pharmacy residency at the Winnipeg Health Sciences Centre.

Pol Vandenbroucke

Chief medical officer, Pfizer Hospital Business Unit

Pol Vandenbroucke

Chief medical officer, Pfizer Hospital Business Unit

Pol Vandenbroucke serves on the Board of BIO Ventures for Global Health, and of the American Federation for Aging Research; He is a member of the Advisory Board of the Steve Biko Centre for Bioethics, University of the Witwatersrand, Johannesburg, South Africa and a Fellow of the Faculty of Pharmaceutical Medicine of the Royal Colleges of Medicine of the United Kingdom. A frequent speaker on health, aging, diversity and policy issues, he is also a Visiting Senior Lecturer at King’s College and the Module Coordinator for Medical Affairs in the Medicines Development Certificate Program at IFAPP Academy and King’s College London. Mr Vandenbroucke’ s career has been dedicated to Clinical Development and Medical Affairs and has included stints in the U.S., Europe, Asia, and Latin America. Before his current position, he was Chief Development Officer for Pfizer Essential Health, Head of Medical Strategy for Pfizer Inc. and VP Medical Affairs of Pfizer’s Essential Health portfolio in North America. He previously also led the Clinical Development of all Pfizer compounds in Asia, Central/Eastern Europe, Latin America, and Africa-Middle East and of Pfizer’s Established Products globally. He was also responsible for developing compounds specifically for diseases of the developing world, such as malaria and river blindness.

Tom Standage

Deputy editor, The Economist

Tom Standage

Deputy editor, The Economist

Tom Standage is the deputy editor of The Economist. He is also responsible for the newspaper's digital strategy and the development of new digital products, including Espresso and Economist Films. He is also the author of six history books, including Writing on the Wall (2013), A History of the World in 6 Glasses (2005) and The Victorian Internet (1998). He studied engineering and computing at Oxford University and has written for other publications including the New York Times, Daily Telegraph, Guardian and Wired, taking a particular interest in the internet's cultural and historical significance. He joined The Economist as science correspondent in 1998 and was subsequently appointed technology editor, business editor and digital editor.

11:00 AM

BREAK

11:30 AM

Spotlight: Science 101

If developing antibiotics were simple, there would be more than one or two prospects in the pipeline, even for the most resistant Gram-negative bacterial infections. Why is the science so hard, and what prospective antibiotics look most promising?

Iruka N Okeke

Professor, University of Ibadan, Nigeria

Iruka N Okeke

Professor, University of Ibadan, Nigeria

Iruka N Okeke is a member of Nigeria’s Technical Working Group on Antimicrobial Resistance and is instituting genomic surveillance of antimicrobial resistance as part of a collaborative National Institute for Health-supported Global Health Research Unit. Ms Okeke is a professor of pharmaceutical microbiology at the University of Ibadan, Nigeria and an African research leader supported by the UK Medical Research Council MRC and Department for International Development. Her research group investigates the mechanisms bacteria use to colonise humans, cause disease and gain drug resistance. She also studies laboratory practice in Africa.

Ms Okeke is a fellow of the Nigerian and the African Academies of Science. She is extensively published in the fields of microbiology, genetics and science and technology studies and is the editor-in-chief of the African Journal of Laboratory Medicine. Iruka is on the Wellcome Trust’s Surveillance and Epidemiology of Drug Resistant Infections Consortium (SEDRIC) advisory board and currently serves as a drug resistance consultant to the Nigeria Centre for Disease Control (CDC), WHO and other organisations.

Slavea Chankova

Healthcare correspondent, The Economist

Slavea Chankova

Healthcare correspondent, The Economist

Slavea Chankova is The Economist’s health-care correspondent. She was previously on the data journalism team and the Britain section, writing about health, gender, science and social policy trends. She joined The Economist in 2015. Before that she worked in international development and economic consulting. She is a graduate of Princeton University.

11:50 AM

Panel: The (private-sector) investment conundrum

If new classes of antibiotics are to be used sparingly or squirrelled away for last use, why invest in their development? This conundrum—in which the old model of volume-based reimbursement is failing—sits at the heart of why pharma companies are no longer interested in investing in antibiotics, and why the pipeline is so weak. Several initiatives have sought to identify “pull” incentives that will reward successful R&D outcomes and thereby persuade pharma to re-engage in drug development. So far, industry remains unconvinced, and governments are reluctant. Yet solving this market failure is a matter of urgency. What incentives show the most potential, and can they be made to work?

Kevin Outterson

Executive director and principal investigator, CARB-X

Kevin Outterson

Executive director and principal investigator, CARB-X

Kevin Outterson teaches health care law at Boston University, where he co-directs the Health Law Program. He serves as the executive director and principal investigator for CARB-X, a $540M international public-private partnership to accelerate global antibacterial innovation. Key partners in CARB-X include the US Government (BARDA & NIAID), the Wellcome Trust, the UK Government (GAMRIF, DHSC), the German Federal Ministry of Education and Research, and the Bill & Melinda Gates Foundation.

His research work focuses on the law and economics of antimicrobial resistance. Mr Outterson was a founding member of the Antimicrobial Resistance Working Group at the CDC. He was a senior consultant on the Eastern Research Group study on antibiotic markets for FDA/HHS. Starting in October 2014, he joined DRIVE-AB, a three-year €9 million project on antibiotic business models sponsored by the European Union’s Innovative Medicines Initiative. Professor Outterson also serves on the Advisory Panel for the Longitude Prize for an inexpensive rapid point-of-care antibiotic diagnostic. Professor Outterson was given the 2015 Leadership Award by the Alliance for the Prudent Use of Antibiotics for his research and advocacy work. He has testified before Congress, Parliamentary working groups, WHO, and several state legislatures.

Anand Anandkumar

Chief executive and managing director, Bugworks

Anand Anandkumar

Chief executive and managing director, Bugworks

Anand Anandkumar is co-founder and chief executive of Bugworks, a leading pharma start-up, one of a handful of companies working on developing novel classes of antibiotics to tackle the global problem posed by multi-drug resistant bacterial superbugs. The company’s lead asset, which is in preclinical development, is a novel dual target inhibitor with excellent potency against the entire list of WHO critical, high and medium threat pathogens. The company has won many national and international innovation awards including the best start-up in India (2015), Economic Times Top Innovator award (2017), first company outside north America and Europe to win the coveted CARB-X grant, and has been featured in the CB-InSights 2019 list of top 36 global start-ups. Bugworks has prominently featured on leading global platforms including the BBC, Wellcome Trust, UNCTAD, CDC and Forbes. Mr Anandkumar was previously co-founder and managing director, Cellworks, a company specialising in personalised oncotherapy, using mathematical modelling frameworks. He is also the co-founder of the India semiconductor association (IESA), member of executive committee of India Biotech association (ABLE), member of Eta-Kappa-Nu and Tau-Beta-Pi International Engineering honors societies, and most recently elected to the board of the AMR Industry alliance.

Nina Grundmann

Senior manager, global health and economic policy, IFPMA

Nina Grundmann

Senior manager, global health and economic policy, IFPMA

Nina Grundmann joined the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) in June 2012. She leads IFPMA’s work on antimicrobial resistance and heads the secretariat of the AMR Industry Alliance, which represents more than 100 pharmaceutical companies. Nina has also worked on vaccine regulatory and programmatic policy and influenza vaccines. Nina holds a master’s degree in International Affairs from the French Institute of Political Studies and a post-graduate degree in Risk Management from HEC Business School in Paris. Prior to joining IFPMA, Nina worked at Sanofi Pasteur on vaccination policy and advocacy and for the Mérieux Foundation to help enhance research capabilities in developing countries.

Aleks Engel

Partner, Novo Holdings A/S

Aleks Engel

Partner, Novo Holdings A/S

Aleks Engel is a partner with Novo Holdings A/S based out of Copenhagen. He is also the director of the REPAIR Impact Fund, a $165m fund investing in early stage novel anti-microbial therapies targeting drug-resistant pathogens. Aleks joined Novo Holdings A/S in September 2014.

Prior to joining Novo Holdings, Aleks was employed as Vice President in Baxter International in Illinois and Shanghai, working with global M&A licensing, growth strategies, investment prioritization and go-to-market planning. Other previous employments include Pfizer Global Research and Development, and McKinsey & Company (all U.S.A.).

Aleks holds a Ph.D. in Biochemical Engineering (1999) and a M.Sc. in Chemical Engineering Practice (1995) from Massachusetts Institute of Technology.

Elizabeth Sukkar

Editor, Thought Leadership, The Economist Intelligence Unit

Elizabeth Sukkar

Editor, Thought Leadership, The Economist Intelligence Unit

Elizabeth is an editor in the Economist Intelligence Unit’s Thought Leadership team. She has been a journalist and editor for more than 15 years, covering healthcare policy, R&D and science for medical journals and UK newspapers, including the British Medical Journal and the Guardian. Before joining the EIU, she was the deputy news editor at the Royal Pharmaceutical Society, where she ran the news and analysis desk, and was often called to comment about healthcare issues on BBC radio. She also managed a team of international journalists when she was the world editor of Informa’s Scrip Intelligence, a global publication on pharmaceutical and healthcare policy, where she won the Informa Journalist of Year award. Before moving into journalism, Elizabeth worked as a pharmacist in community, hospital and health authority settings.

12:25 PM

Panel: The (public-sector) investment conundrum

With pharma companies unable or unwilling to invest in the long-term sustainable financing of antibiotic and antimicrobial R&D, governments may need to play a greater role. Some have suggested we should regard measures to reduce AMR similarly to infrastructure investment: as a critical public good worthy of public investment.

What other government-led approaches might prove sustainable?

How can governments form a “coalition of the willing” to find long-term development solutions? What might the obstacles be?

What role can large developing countries such as China and India play?

Christopher Fearne

Minister for health, Malta

Christopher Fearne

Minister for health, Malta

Christopher Fearne was appointed minister for health after holding the position of parliamentary secretary for health since April 2014. In June 2017 he was re-appointed minister for health following the general elections and in July 2017 he was elected deputy prime minister following the Malta Labour Party’s extraordinary general council. Prior to this, Mr Fearne worked as a consultant paediatric surgeon and clinical chairman at Mater Dei Hospital. He is a member of parliament for the ruling Labour Party and was the chairman of the Foreign and European Affairs Committee at the Maltese House of Representatives.

Hon. Fearne has worked as a doctor and surgeon for over 30 years. He received his formal education at St. Aloysius College and at the University of Malta graduating in Medicine and Surgery in 1987, becoming a Fellow of The Royal College of Surgeons of Edinburgh. He worked and studied in a number of children’s hospitals in England, including the Great Ormond Street Hospital in London. He also lectures students of medicine at the University of Malta.

Clare Chandler

Director, antimicrobial resistance centre, London School of Hygiene and Tropical Medicine

Clare Chandler

Director, antimicrobial resistance centre, London School of Hygiene and Tropical Medicine

Clare Chandler is an associate professor in Medical Anthropology and director of the Antimicrobial Resistance Centre at the London School of Hygiene and Tropical Medicine. Ms Chandler has spent the past decade and a half researching how people use medicines and how health care is enacted across different low and middle income country settings. She leads a large research group to explore the ways societies around the globe have become reliant on antimicrobial medicines not only for treatment of illnesses but in anticipation of infections in humans, animals and in crops, and how this relates to wider economic and political imperatives. Her projects include the Anti-Microbials in Society (AMIS) Hub, an online resource of high quality social research on AMR. Clare provides technical advice about behavioural aspects of global health, for example on malaria, Ebola, and antimicrobial resistance, to various governmental and multi-lateral agencies.

Manica Balasegaram

Executive director, GARDP

Manica Balasegaram

Executive director, GARDP

Manica Balasegaram trained as a medical doctor at the University of Nottingham, UK from where he started his career in internal and emergency medicine. From 2001, he worked as a doctor and researcher in several countries in sub-Saharan Africa and South Asia and gained important experience in emergency medicine during humanitarian interventions, including with Doctors Without Borders (MSF).

At the end of 2007, he joined the Drugs for Neglected Diseases initiative (DNDi) as Head of the Leishmaniasis Clinical Program, a position he held for four years before returning to MSF as Executive Director of their Access to Essential Medicines Campaign in Geneva. In June 2016, he was appointed Director of GARDP and its Executive Director in July 2018.

Mr Balasegaram is currently a member of the Board of Directors of the Medicines Patent Pool (MPP) and the Scientific Advisory Board of FIND, two Geneva-based organizations. He has also been a lecturer since 2013 at the University of Geneva for a Diploma and Master of Advanced Studies (MAS) program in clinical research and development.

An expert in global health and infectious diseases, Mr Balasegaram is also recognized for his international work on health policies and access to medicines. He also has experience in clinical trials and drug development as a lead investigator and in project management.

Nobuko Ichikawa

Senior environmental advisor, The European Bank for Reconstruction and Development (EBRD)

Nobuko Ichikawa

Senior environmental advisor, The European Bank for Reconstruction and Development (EBRD)

Nobuko Ichikawa is a senior environmental advisor in the Environment Department of the European Bank for Reconstruction and Development (EBRD) in London, U.K. Since the UN resolution to combat the proliferation of AMR was issued in September 2016, she has been working on AMR initiatives to effectively recognise AMR risks and take adequate mitigation measure at the project level as well through the policy dialogue. She has been working in EBRD since 1996 and prior to EBRD, she had worked in the World Bank in Washington D.C. from 1991 to 1996. Her work in EBRD focuses on environmental due diligence for the health care services, PPP hospital facilities, property and tourism, information technologies/telecommunication, urban redevelopment and cultural heritage and social inclusion in EBRD countries of operations. With the World Bank, she worked on industrial pollution prevention policy work in Vietnam, Thailand and Malaysia. She obtained a master in urban studies and city planning in MIT in Cambridge, M.A., master in Hosei University and bachelor in Chuo University in Tokyo. Nobuko has been working and living in Thailand, the U.S. and U.K for the last 30 years.

Tom Standage

Deputy editor, The Economist

Tom Standage

Deputy editor, The Economist

Tom Standage is the deputy editor of The Economist. He is also responsible for the newspaper's digital strategy and the development of new digital products, including Espresso and Economist Films. He is also the author of six history books, including Writing on the Wall (2013), A History of the World in 6 Glasses (2005) and The Victorian Internet (1998). He studied engineering and computing at Oxford University and has written for other publications including the New York Times, Daily Telegraph, Guardian and Wired, taking a particular interest in the internet's cultural and historical significance. He joined The Economist as science correspondent in 1998 and was subsequently appointed technology editor, business editor and digital editor.

1:00 PM

PANEL: OUT OF THE SHADOWS

Poor-quality and counterfeit drugs can increase infection rates, undermine data collection on AMR and reduce the incentive for investment in new medicines. Counterfeits expose pathogens to sub-therapeutic doses of medicine and thereby fuel AMR. This problem is particularly acute in developing countries. These countries are already under the spotlight for offering less-controlled access to antibiotics. How can surveillance of the supply chain be improved to stop substandard medicines reaching the market?

Martin Seychell

Deputy director-general, Directorate-General for Health and Food Safety, European Commission

Martin Seychell

Deputy director-general, Directorate-General for Health and Food Safety, European Commission

A graduate in chemistry and pharmaceutical technology, Martin Seychell specialized in Chemical analysis. He has held important positions on several government boards and commissions in Malta, including the Food Safety Commission and the Pesticides Board. Martin Seychell occupied the post of Head of Directorate at the Malta Standards Authority between 2001 and 2006. He has been responsible for the implementation of a number of EU directives in the areas of risk assessment, food safety, chemicals and cosmetic products legislation, and has actively participated in negotiations on major technical proposals such as the new chemicals legislation, REACH, and in screening processes in the areas of free movement of goods, environment and agriculture during the process leading to Malta's accession to the EU. He held the post of Director of Environment in Malta between 2006 and 2011. As Director, he was responsible for a broad range of functions arising from the Maltese Environment Protection Act. He was appointed Deputy Director General for Health and Consumers at the European Commission in March 2011. Responsible for directorates dealing with Consumer affairs, Public health and Health systems and products (SANCO). 2014 - to date: Deputy Director-General for Health in the Health and Food Safety Directorate-General (SANTE).

Harshika Sarbajna

Global head of anti-infectives, Sandoz

Harshika Sarbajna

Global head of anti-infectives, Sandoz

Harshika Sarbajna is the global head of anti-infectives for Sandoz, a Novartis Division. In this role, she is responsible for ensuring sustainable growth of the antibiotics portfolio at Sandoz, the largest provider of generic antibiotics globally, working closely with markets and various functions within Sandoz. In this role, she is also spearheading Sandoz & Novartis wide AMR Stewardship program, bringing together stakeholders both inside and outside the organisation. She previously served as the global head of strategy and operations of the Biosimilars business unit within Sandoz, and was part of the business leadership team. During Harshika’s tenure, she successfully led development and implementation of the commercial, portfolio and manufacturing strategy of the biosimilars business that delivered two successful biosimilar launches in Europe, and double-digit growth of in-market products across the globe.

Prior to Sandoz, Ms Sarbajna served as the head of business strategy for the biosimilars business at Dr. Reddy’s Lab, and drove growth across the portfolio in key markets including US, Asia, Latin America and Russia. Before joining Dr. Reddy’s, she led various executive-level advisory engagements on business and growth strategy for large Corporates and PE funds as principal consultant with The Parthenon Group.

Jaideep Gogtay

Global chief medical officer, Cipla

Jaideep Gogtay

Global chief medical officer, Cipla

Jaideep Gogtay is the global chief medical officer at Cipla and has been associated with the organisation for nearly 25 years now. At Cipla, he has been closely involved in the development and introduction of several drugs in
various therapeutic fields, particularly in HIV/AIDS, infectious diseases and respiratory diseases. He has worked on several clinical trials in the field of asthma, COPD and infectious diseases. He was a key member of the team which introduced several antiretroviral drugs for
the treatment of AIDS including the 1$ a day triple drug cocktail. Cipla has a large number of anti-infective drugs including antibiotics, anti-viral and anti-fungal which are available in a number of countries. As head of medical affairs, he was responsible for bringing back ‘old’ antibiotics such as Colistin which was reintroduced in India after over 50 years. One of the areas that Cipla continues to work is to update physicians on appropriate use of antibiotics and the current challenges of antimicrobial resistance, both in the community and in the hospital.
He was a member of the Association of Physicians of India (Guidelines 2005) on ‘Antiretroviral therapy’. He has 40 publications to his credit including chapters on Pharmacokinetics and Pharmacodynamics of antibiotics and has presented papers at over 50 conferences. He was
involved in setting up the Chest Research Foundation (CRF), now an independent research center dedicated to research in the field of respiratory medicine. He is a frequent presence in workshops on research methodology at academic institutions and at several national and
international forums.

Charles Goddard

Editorial director, global initiatives, The Economist Group

Charles Goddard

Editorial director, global initiatives, The Economist Group

Charles Goddard leads the Economist Intelligence Unit’s editorial services in Asia-Pacific, including Corporate Network, a peer group for senior decision-makers of global businesses operating in the region. A journalist by background, he has worked across a range of publications and services at the Economist Intelligence Unit, including as author of the China Market Atlas series and director of its research divisions. A frequent traveller and speaker, he interacts regularly with business and government leaders across Asia. He is also executive director of The Economist’s World Ocean Summit, a global series of events on the sustainable use of our seas.

1:30 PM

LUNCH

2:00 PM

Lunch panel: Drug-resistant TB

Sponsored by Johnson & Johnson

Today, DR-TB is the leading contributor to AMR, causing approximately one-third of all AMR-related deaths. New innovations – including novel rapid diagnostic tests and a shorter, more effective DR-TB treatment regimen – have the potential to turn the tide. To do so, requires overcoming barriers like funding gaps, the slow uptake of new tools, missing data, and a lack of patient empowerment. The economic imperative to act now is clear. DR-TB comes at a heavy cost to patients, their families and entire economies. Every year in fact, DR-TB related deaths cost the global economy at least $14 billion in future loss of GDP. How can we translate this investment case into global action, in order to change the trajectory of this growing public health crisis?

Lucica Ditiu

Executive director, Stop TB Partnership

Lucica Ditiu

Executive director, Stop TB Partnership

Lucica Ditiu is a Romanian physician and public health expert who has devoted her career to helping and supporting people affected by TB, especially those most vulnerable, most stigmatised and living in impoverished communities. Lucica Ditiu has led the Stop TB Partnership for the last 7 years. Under her leadership, the organisation has gained a clear identity and evolved into a lean, innovative and progressive team that represents one of the strongest advocacy voices on global health and tuberculosis, providing support - financial as well as TB medicines and diagnostics – for a TB response towards a world without TB. A strong believer in innovation, flexibility and change, Dr. Ditiu is relentless in pushing for the inclusion of all people affected by TB, with an ambitious agenda of transparency and accountability that continuously challenges the status quo.

Dr. Ditiu is a specialist in lung diseases and began practicing medicine in 1992 in Romania. She started her international career with the WHO in January 2000 as a medical officer for TB in Albania, Kosovo and Macedonia within the disaster and preparedness unit. She has worked for the past 18 years in the WHO and UN system at every level: national, sub regional, regional and global, and attributes her experience and expertise to delivering results while navigating all sorts of difficulties.

Adrian Thomas

Vice-president, global public health, Johnson & Johnson

Adrian Thomas

Vice-president, global public health, Johnson & Johnson

Adrian Thomas is the vice-president, Global Access, Programs & Policy, within the Johnson & Johnson Global Public Health organisation. Adrian has a special interest in the fields of public health, commercial and market access strategy, and pharmaceutical policy. He also held numerous roles in market access, including Global Head Health Economics & Market Access Medical Devices and Global Head of Market Access for Janssen, the pharmaceutical companies of Johnson & Johnson. He has also held roles in risk management and drug safety, including Global Head of Benefit Risk Management and Chief Safety Office for Janssen.

Prior to joining J&J, Adrian held roles in regional medical affairs, drug development and product management for Schering-Plough and Eli Lilly. He is a clinical pharmacologist and vascular physician by training with experience in clinical trials design and methodology.

Adrian is a Fellow of the Royal Australasian College of Physicians and the College of Medical Administrator’s. He received his Bachelor of Medicine and Bachelor of Surgery degrees from the University of Melbourne in Australia.

Vanessa Candeias

Head, shaping the future of health and healthcare, World Economic Forum

Vanessa Candeias

Head, shaping the future of health and healthcare, World Economic Forum

Trained as a nutritionist, Faculty of Nutrition and Food Sciences, Porto University; Master’s in Public Health, London School of Hygiene and Tropical Medicine. Formerly: worked at national level on developing and implementing health promotion policies with the Ministry of Health in Portugal and the Institute of Preventive Medicine of the University of Lisbon; worked with the World Health Organization Headquarters on global guidelines and policy development for noncommunicable diseases. Currently, Head of System Initiative on Shaping the Future of Health and Healthcare and Member of the Executive Committee, World Economic Forum. The System Initiative on Shaping the Future of Health and Healthcare provides a dynamic platform for leading businesses, governments, civil society organizations and world class experts to shape the global health agenda; co-design and accelerate the implementation of collaborative approaches that transform the health ecosystem – across prevention, diagnosis, treatment, cure and maintenance of health; and ultimately enables populations to live healthier lives and have access to the care they need when they need it.

Eliud Wandwalo

Senior disease co-ordinator for TB, The Global Fund

Eliud Wandwalo

Senior disease co-ordinator for TB, The Global Fund

Eliud joined the Global Fund in 2013. As the senior disease co-ordinator, he serves as the primary point for leadership and strategic guidance on TB, collaborating across the Global Fund secretariat and external partners to ensure Global Fund resources are strategically invested for impact. Before joining the Global Fund, Eliud worked with Management Sciences for Health (MSH) as regional principal technical advisor for TB supporting African countries. Prior to that Eliud worked with National TB Programme in Tanzania for over 10 years. Eliud completed his medical training from University of Dar Es Salaam, Tanzania and his master and PhD studies from Bergen University in Norway.

Tom Standage

Deputy editor, The Economist

Tom Standage

Deputy editor, The Economist

Tom Standage is the deputy editor of The Economist. He is also responsible for the newspaper's digital strategy and the development of new digital products, including Espresso and Economist Films. He is also the author of six history books, including Writing on the Wall (2013), A History of the World in 6 Glasses (2005) and The Victorian Internet (1998). He studied engineering and computing at Oxford University and has written for other publications including the New York Times, Daily Telegraph, Guardian and Wired, taking a particular interest in the internet's cultural and historical significance. He joined The Economist as science correspondent in 1998 and was subsequently appointed technology editor, business editor and digital editor.

3:00 PM

Strategy session I : Vaccines

Sponsored by Pfizer

Infection prevention is the foundation of reducing AMR and the role of vaccines in combating AMR remains undervalued and underutilised. Vaccines are one of the early lines of defense and can address AMR through multiple pathways. Today, there are few licensed vaccines for the bacteria that are widely-regarded as urgent AMR threats and, where they do exist, their inclusion in national action plans and overall utilisation, does not maximise their potential benefit. Sub-optimal implementation of current vaccines disincentivises research and development investment needed to explore and develop future vaccines. How can we activate and engage the entire stakeholder spectrum to fully maximise the promise of vaccines in reducing AMR?

Pfizer is a diamond sponsor of this event and the named sponsor for this Vaccines strategy session. Pfizer has had no input into the agenda or content of the presentations in this session.

David Salisbury

Former director of immunisation, Department of Health, London

David Salisbury

Former director of immunisation, Department of Health, London

David Salisbury was made a Companion of the Order of the Bath in the Queen’s Birthday Honours, 2001, for his services to immunisation. Mr Salisbury was director of immunisation at the Department of Health, London, until 2014; he was responsible for the UK national immunisation programme. During that time he introduced numerous new vaccines, dealt with the MMR autism crisis and advised other governments and international organisations.
He is chair of the board of the Jenner Vaccine Foundation and was inaugural president of the International Association of Immunisation Managers. Mr Salisbury continues to work extensively with the WHO on the Global Programme for Vaccines. He was the chair of the WHO Strategic Advisory Group of Experts on Vaccines from 2005 to 2010. He is chair of the Global Commission for Certification of Poliomyelitis Eradication and chair of the European Region Certification Commission for Poliomyelitis Eradication. He serves on advisory boards for four EC-funded vaccine research projects. He has also had extensive experience in Global Health Security having co-chaired a G7 working group on pandemic influenza for nine years.

Mr Salisbury trained as a paediatrician at Oxford and at the Hospital for Sick Children, Great Ormond Street, London. He is a fellow of the Royal College of Physicians, fellow of the Royal College of Paediatrics and Child Health, fellow of the Faculty of Public Health, and fellow of the Academy of Medical Sciences. He has an honorary chair at Imperial College, London and is an associate fellow at the Centre on Global Health Security, Royal Institute of International Affairs, Chatham House, London.
Mr Salisbury has written around 100 publications on immunisation and paediatric topics.

Wilson Mok

Head of policy, Gavi, The Vaccine Alliance

Wilson Mok

Head of policy, Gavi, The Vaccine Alliance

Wilson Mok serves as the head of policy at Gavi, the Vaccine Alliance. In this role he oversees Gavi’s vaccine investment decision-making and programmatic policies. Prior to joining Gavi in 2013, Wilson served as a strategy consultant at the Bill & Melinda Gates Foundation, focusing on antiretroviral-based HIV prevention. He was also previously a management consultant with McKinsey & Co based in New York, advising healthcare companies and public sector clients. Wilson holds degrees in chemical engineering from the University of California at Berkeley and the Massachusetts Institute of Technology.

Philip Howard

Philip Howard

Philip Howard is Consultant Pharmacist in Antimicrobials at the Leeds Teaching Hospitals NHS Trust, National AMR Project Lead at NHS-Improvement and Honorary Visiting Professor at Leeds University. He is a spokesman for the Royal Pharmaceutical Society on Antimicrobials, and for the Antibiotic-Action and British Society of Antimicrobial Chemotherapy charities. He was a member of the Dept of Health ARHAI Antimicrobial Stewardship Group that produced the original Start Smart then Focus Antimicrobial Stewardship Guidelines, and the HPA Primary Care Unit which helped produce the RCGP TARGET guidance on Antimicrobial Stewardship in Primary Care. His research interests include Antimicrobial Stewardship, and led the first global hospital Antimicrobial Stewardship survey. He has been involved in AMS education and training across the world. He’s won the GHP/GSK/UKCPA Clinical Leadership Award and the UKCPA Lifetime Achievement Award

Adam Cunningham

Co-director, Bacterial Vaccines (BactiVac) Network

Adam Cunningham

Co-director, Bacterial Vaccines (BactiVac) Network

Adam Cunningham is professor of Functional Immunity at the University of Birmingham. He is Co-Director of the Bacterial Vaccines (BactiVac) Network. This Global Challenges Research Fund/Medical Research Council funded global network links and supports researchers from around the world to accelerate the development and use of vaccines against bacterial infections, particularly those of relevance to Low and Middle Income Countries. In addition to this role, Adam has an active research portfolio that focuses on how bacterial infections can harm us and how the immune system can protect us against infection, both naturally and after vaccination. Adam’s research on vaccines focuses on how we respond to vaccines, how we can improve the protection they offer and how we can make vaccines work more efficiently in those groups of people most vulnerable to infections.

Elizabeth Sukkar

Editor, Thought Leadership, The Economist Intelligence Unit

Elizabeth Sukkar

Editor, Thought Leadership, The Economist Intelligence Unit

Elizabeth is an editor in the Economist Intelligence Unit’s Thought Leadership team. She has been a journalist and editor for more than 15 years, covering healthcare policy, R&D and science for medical journals and UK newspapers, including the British Medical Journal and the Guardian. Before joining the EIU, she was the deputy news editor at the Royal Pharmaceutical Society, where she ran the news and analysis desk, and was often called to comment about healthcare issues on BBC radio. She also managed a team of international journalists when she was the world editor of Informa’s Scrip Intelligence, a global publication on pharmaceutical and healthcare policy, where she won the Informa Journalist of Year award. Before moving into journalism, Elizabeth worked as a pharmacist in community, hospital and health authority settings.

3:00 PM

Strategy Session II: Diagnostics

In the United States, one antibiotic prescription in three is unnecessary, according to the Centres for Disease Control. Better diagnostics that help identify quickly whether an infection is bacterial (and therefore treatable by antibiotics) will be a key tool in ensuring that antibiotics are used only when they are needed. What progress is being made in discovering new diagnostic tools? What are the right incentives to accelerate their development, and what are the hurdles to getting these in place?

Danuta Cichocka

Chief executive, Resistell

Danuta Cichocka

Chief executive, Resistell

Danuta Cichocka is a co-founder, chief executive and a chairperson of the Board of Directors at Resistell AG, the Swiss Federal Institutes of Technology (EPFL) spin-off developing fast and simple nano-motion based alternative to culture-based antibiogram. The company’s mission is to provide the physicians with the diagnostic tool that will enable them to choose the most efficient but also most narrow-spectrum antibiotic for the patient.

She is a microbiologist by training. She completed the Ph.D. at the UFZ Leipzig in 2008, followed by a post-doc at the KU Leuven, and a senior researcher position at FHNW in Basel (2012-2017). She has experience in research management and biotechnology policy development at a European level, gained at European Commission in Brussels (2009-2012). In 2016 she completed the Executive MBA program at the EPFL and obtained a Certificate of Advanced Studies (CAS) in Management of Biotech, Medtech & Pharma Ventures. At the beginning of 2017, Danuta initiated the collaboration with EPFL Laboratory of Physics of Living Matter on the commercialisation of nano-motion based technology for phenotypic antibiotic susceptibility testing, which resulted in the incorporation of the start-up in 2018.

Oliver van Hecke

Oliver van Hecke

Oliver van Hecke is a clinical lecturer at the Department of Primary Care Health Sciences, University of Oxford. His PhD focussed on the impact of AMR in the community and the implications for future intervention. His research interests are in optimising antibiotic use for common infections in the community and antibiotic resistance. This stems from his work as a generalist practising in the NHS with first-hand experience of the difficulties that GP’s encounter. He is also a key member of the newly established National Institute for Health Research (NIHR) Community Healthcare MIC (MedTech and In vitro diagnostics Co-operative) based at Oxford, which aims to speed up the development, evaluation, and use of diagnostic tests. As part of the Infections research team at the University of Oxford, he is keen to foster local, national and international collaborations especially in resource-poor settings.

Jesús Rueda Rodríguez

Director International Affairs, MedTech Europe

Jesús Rueda Rodríguez

Director International Affairs, MedTech Europe

Jesús heads the International Affairs team. He is involved in the work at the international level acting as representative to WHO, ISO and as liaison to other associations on all regulatory matters. Directly involved in the discussions on the revision and recast of the IVD Directive, he previously lead the regulatory debates that affect IVDs at EU level until 2016.

Kristina Lagerstedt

Founder and chief executive, 1928 Diagnostics

Kristina Lagerstedt

Founder and chief executive, 1928 Diagnostics

Kristina Lagerstedt is a Swedish tech and healthcare entrepreneur and scientist who founded the digital health company 1928 Diagnostics and serves as its chief executive. 1928 Diagnostics offers a DNA analytics platform to clinical and public health laboratories globally for intelligent infection control and diagnostics with the mission to save the power of antibiotics. 1928 Diagnostics was announced a Technology Pioneer Champion by the World Economic Forum in 2018 and Ms Lagerstedt is a member of Digital Leaders of Europe. Ms Lagerstedt has also worked as a clinical cancer scientist focusing on identifying and commercialising molecular biomarkers for detecting and guiding the treatment of cancer.

Slavea Chankova

Healthcare correspondent, The Economist

Slavea Chankova

Healthcare correspondent, The Economist

Slavea Chankova is The Economist’s health-care correspondent. She was previously on the data journalism team and the Britain section, writing about health, gender, science and social policy trends. She joined The Economist in 2015. Before that she worked in international development and economic consulting. She is a graduate of Princeton University.

4:00 PM

Panel: Making it mainstream

If new antibiotics and other antimicrobial solutions are not developed soon, and in a sustained way, AMR could be a larger killer than cancer by 2050. But the general public remains unaware of this, as do many of those responsible for prescribing antimicrobials. Although there are signs of new groups joining the fray, AMR is far from having the advocacy it needs to move up the global health-security agenda. What can global-health campaigns on issues like HIV/AIDS, TB, malaria and non-communicable diseases such as diabetes teach us about developing a more successful approach to raising awareness of AMR? How might advocates cast a wider net? And can advocacy make a difference anyway?

Keiji Fukuda

Director and clinical professor, school of public health, The University of Hong Kong

Keiji Fukuda

Director and clinical professor, school of public health, The University of Hong Kong

Keiji Fukuda is the director and a clinical professor at The University of Hong Kong School of Public Health. He previously worked at the World Health Organisation (WHO) in several capacities including assistant director-general (ADG) and special representative of the director-general for antimicrobial resistance; ADG for the health security and environment cluster; and director of the Global Influenza Programme. Before that, he worked at the U.S. Centers for Disease Control and Prevention (CDC) as the epidemiology section chief, influenza branch and as a medical epidemiologist in the viral exanthems and herpesvirus branch, National Center for Infectious Diseases. Mr Fukuda has been a global public health leader in many areas including health security; emerging infectious diseases including seasonal, avian and pandemic influenza, SARS, MERS and Ebola; antimicrobial resistance; development of the Pandemic Influenza Preparedness Framework; implementation of the International Health Regulations; food safety; and chronic fatigue syndrome. He has considerable experience in epidemiological research and field investigations, media communications and international diplomatic negotiations including those held to establish a historic heads of state level meeting on antimicrobial resistance at the United Nations in 2016.

Mandeep Dhaliwal

Director, HIV, health and development team, UNDP

Mandeep Dhaliwal

Director, HIV, health and development team, UNDP

MandeepDhaliwal is the director of UNDP’s HIV, Health and Development Group, Bureau of Policy and Programme Support. Ms Dhaliwal brings to the organisation over 20 years of experience working on multi-sectoral HIV and health responses and evidence-based policy and programming in low and middle-income countries. Ms. Dhaliwal joined UNDP in 2008 and was the architect of the Global Commission on HIV and the Law and led the secretariat for the United Nations Secretary-General’s High-Level Panel on Access to Medicine. Prior to joining UNDP, she was a senior adviser to the Dutch Royal Tropical Institute’s Special Programme on HIV/ AIDS. From 2000 to 2006, Ms. Dhaliwal worked for the International HIV/AIDS Alliance’s Policy, Research and Good Practice Team in the United Kingdom where she focused on issues of HIV care and treatment in developing countries. She was instrumental in expanding the International HIV/AIDS Alliance's technical support and policy work on issues of HIV care, treatment and support in Africa, Asia, Eastern Europe and Latin America. From 1993 to 2000, she worked on HIV and human rights issues in India, including as the founding Coordinator of the Lawyers Collective HIV/AIDS Unit, a leading human rights organization, establishing the Unit's legal aid, public interest litigation, legal literacy and policy/advocacy work.

Mark Pearson

Deputy director, employment, labour and social affairs, OECD

Mark Pearson

Deputy director, employment, labour and social affairs, OECD

Mark Pearson is deputy director for Employment, Labour and Social Affairs (ELS) at the OECD. Mr Pearson works with the director to provide leadership in the co-ordination and management of the activities of ELS and ensure that it is at the forefront of the international health, social and employment agenda. Mr. Pearson joined the OECD in 1992, initially working on tax issues. He then moved to ELS, becoming the head of the Social Policy Division from 2000-2008. In 2009 he became head of the Health Division where the central focus of work was on how to deliver health care with greater efficiency. As deputy director since 2015, he has overseen the work of the organisation on topics such as antimicrobial resistance, diversity, inequality and pharmaceutical pricing.

Charles Goddard

Editorial director, global initiatives, The Economist Group

Charles Goddard

Editorial director, global initiatives, The Economist Group

Charles Goddard leads the Economist Intelligence Unit’s editorial services in Asia-Pacific, including Corporate Network, a peer group for senior decision-makers of global businesses operating in the region. A journalist by background, he has worked across a range of publications and services at the Economist Intelligence Unit, including as author of the China Market Atlas series and director of its research divisions. A frequent traveller and speaker, he interacts regularly with business and government leaders across Asia. He is also executive director of The Economist’s World Ocean Summit, a global series of events on the sustainable use of our seas.

4:40 PM

Ask The Economist: Where to next?

In this closing session, a panel of Economist editors will discuss the day’s findings, and where and how to act and invest to ensure continued progress on fighting AMR.

Tom Standage

Deputy editor, The Economist

Tom Standage

Deputy editor, The Economist

Tom Standage is the deputy editor of The Economist. He is also responsible for the newspaper's digital strategy and the development of new digital products, including Espresso and Economist Films. He is also the author of six history books, including Writing on the Wall (2013), A History of the World in 6 Glasses (2005) and The Victorian Internet (1998). He studied engineering and computing at Oxford University and has written for other publications including the New York Times, Daily Telegraph, Guardian and Wired, taking a particular interest in the internet's cultural and historical significance. He joined The Economist as science correspondent in 1998 and was subsequently appointed technology editor, business editor and digital editor.

Charles Goddard

Editorial director, global initiatives, The Economist Group

Charles Goddard

Editorial director, global initiatives, The Economist Group

Charles Goddard leads the Economist Intelligence Unit’s editorial services in Asia-Pacific, including Corporate Network, a peer group for senior decision-makers of global businesses operating in the region. A journalist by background, he has worked across a range of publications and services at the Economist Intelligence Unit, including as author of the China Market Atlas series and director of its research divisions. A frequent traveller and speaker, he interacts regularly with business and government leaders across Asia. He is also executive director of The Economist’s World Ocean Summit, a global series of events on the sustainable use of our seas.

Elizabeth Sukkar

Editor, Thought Leadership, The Economist Intelligence Unit

Elizabeth Sukkar

Editor, Thought Leadership, The Economist Intelligence Unit

Elizabeth is an editor in the Economist Intelligence Unit’s Thought Leadership team. She has been a journalist and editor for more than 15 years, covering healthcare policy, R&D and science for medical journals and UK newspapers, including the British Medical Journal and the Guardian. Before joining the EIU, she was the deputy news editor at the Royal Pharmaceutical Society, where she ran the news and analysis desk, and was often called to comment about healthcare issues on BBC radio. She also managed a team of international journalists when she was the world editor of Informa’s Scrip Intelligence, a global publication on pharmaceutical and healthcare policy, where she won the Informa Journalist of Year award. Before moving into journalism, Elizabeth worked as a pharmacist in community, hospital and health authority settings.

Slavea Chankova

Healthcare correspondent, The Economist

Slavea Chankova

Healthcare correspondent, The Economist

Slavea Chankova is The Economist’s health-care correspondent. She was previously on the data journalism team and the Britain section, writing about health, gender, science and social policy trends. She joined The Economist in 2015. Before that she worked in international development and economic consulting. She is a graduate of Princeton University.

Sponsors

Supported by

The Pew Charitable Trusts

Established in 1948, The Pew Charitable Trusts is a global nongovernmental organization committed to improving public policy, informing the public, and invigorating civic life. Pew is driven by the power of knowledge to solve today’s most challenging problems.

The Pew Research Center, a subsidiary of The Pew Charitable Trusts, is a nonpartisan fact tank that informs the public about the issues, attitudes and trends shaping the world. It does not take policy positions. The center conducts public opinion polling, demographic research, content analysis and other data-driven social science research.

Diamond sponsors

Diamond sponsors

Johnson & Johnson

At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That’s why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today, as the world’s largest and most broadly based healthcare company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere.

Every day, our more than 130,000 employees across the world are blending heart, science and ingenuity to profoundly change the trajectory of health for humanity.

Diamond sponsors

Pfizer

At Pfizer, we strive to set the standard for quality, safety and value in our health care products. Every day, Pfizer colleagues work to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. As one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world.

Platinum sponsor

Platinum sponsor

MSD

From developing new therapies that treat and prevent disease to helping people in need, we're committed to improving health and wellbeing around the world.

We are inspired by the difference we can make in the lives of people around the world through innovative medicines, including biologic therapies, and animal health products. Our products cover a broad range of areas, including cardiovascular disease and immunology, infectious diseases, and women's health. And we focus our research on conditions that affect millions of people around the world - diseases like Alzheimer's, diabetes and cancer - while building strengths in new areas like biologics.

Silver sponsor

Silver sponsor

Sandoz

Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars and a pioneer in the emerging field of prescription digital therapeutics. Our purpose is to pioneer access to healthcare by developing and commercializing novel, affordable approaches that address unmet medical need.

Part of

Part of

The Evidence Initiative

The Evidence Initiative, a project of The Economist Group and The Pew Charitable Trusts, explores the use of facts and data in decision-making today and presents the case for evidence-based policies. As part of the initiative, the Economist Intelligence Unit will produce an Evidence Index in October 2019, which will assess the availability and quality of evidence in the Group of 20 countries.

Official PR agency

Official PR agency

Grayling

Supporting organisation

ABPI

The ABPI represents innovative research-based biopharmaceutical companies leading an exciting new era of biosciences in the UK. Our industry brings life-saving and life-enhancing medicines to patients. We represent companies who supply more than 80 per cent of all branded medicines used by the NHS and who are researching and developing the majority of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome the disease.

Supporting organisation

UNDP

UNDP works on HIV, Health and development with a broad range of multi sectoral partners at global, regional, national and local levels, including governments, UN agencies and other intergovernmental organisations, multilateral and bilateral donors, development banks, the private sector and other development partners.UNDP’s commitment to HIV and other major health challenges is based on the principles that health is both a driver and outcome of development, and that actions across a wide range of development sectors have a significant impact on health outcomes. As the host member agency of the UN Interagency Task Team on Sustainable Procurement in the Health Sector (SPHS), UNDP focuses on addressing the social, economic and environmental determinants of health, which are primarily responsible for health inequalities.

Supporting organisation

EFPIA - European Federation of Pharmaceutical Industries and Associations

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.

Supporting organisation

British Society for Antimicrobial Chemotherapy (BSAC)

BSAC is a learned society whose members are among the world’s leading infectious disease physicians, pharmacists, microbiologists, and nurses.With more than 45 years of leadership in antibiotic research and education, BSAC is dedicated to saving lives by fighting infection. It does this by supporting a global network of experts via workshops, conferences, evidence-based guidelines, e-learning courses, and its own high-impact international journal.BSAC also provides national surveillance and susceptibility testing programmes, an outpatient parenteral antimicrobial therapy (OPAT) initiative, research and development grants, and the secretariat for the All-Party Parliamentary Group on Antibiotics.BSAC has members in 40 nations and active learners in more than 135 countries.Tracey Guise
Chief Executive Officer
British Society for Antimicrobial Chemotherapy (BSAC)
53 Regent Place, Birmingham B1 3NJ
+44(0)121 236 1988
tguise@bsac.org.uk
www.bsac.org.uk

Supporting organisation

Pharma Boardroom

PharmaBoardroom is a global platform that connects the experiences and expertise of C-level executives throughout the world. Covering management strategy, regulatory reforms, R&D, market access and pricing, PharmaBoardroom offers a seat at the table with pharma leaders and decision makers. We do this by providing unparalleled content that informs, engages and inspires senior professionals to help them understand global trends and strategies and translate them into local realities.

Supporting organisation

BIA

Established over 25 years ago at the infancy of biotechnology, the BioIndustry Association (BIA) is the trade association for innovative life sciences in the UK. Our goal is to secure the UK's position as a global hub and as the best location for innovative research and commercialisation, enabling our world-leading research base to deliver healthcare solutions that can truly make a difference to people's lives.

Supporting organisation

NI AMR Network

The NI AMR Network is a One Health focused, multidisciplinary group bringing together academia, business and public sectors across Northern Ireland to address challenges posed by AMR. Members span human and animal medicine, microbiology, environmental science, diagnostics, chemistry, engineering, data analytics, policy and public health.

Supporting organisation

UKIHMA

The UK International Healthcare Management Association provides streamlined access to high-quality health care organisations and consortia, from the NHS and the private sectors delivering bespoke partnerships to the specific needs of clients. In short, it represents a single front door to the best of UK healthcare expertise.

Supporting organisation

European Medical Journal

The European Medical Journal is an independent, open-access eJournal dedicated to delivering first-class insights into ground-breaking changes, and advancements in medicine. Spanning sixteen therapeutic areas, including Innovations, Cardiology, Oncology, and more, each journal provides the reader with the latest medical congress highlights, abstract reviews, and peer-reviewed articles to name but a few of its wide content selection. Flagship EMJ journals are also published quarterly, bringing an assortment of research papers from a variety of topics.

Speaking opportunities

Sponsorship opportunities

Download Brochure

The Economist Events is a part of the Economist Group. We would love to keep you informed about other Economist events, newly-released content, our best subscription offers, and great new product offerings from The Economist Group.

I wish to be contacted by email.

I also wish to sign up to the EIU (Economist Intelligence Unit) Perspectives newsletter.

The Economist Group is a global organisation and operates a strict privacy policy around the world. Please see our privacy policy here

Attending Request

By submitting this form we will send you updates associated with this event.

The Economist Events is a part of the Economist Group. We would love to keep you informed about other Economist events, newly-released content, our best subscription offers, and great new product offerings from The Economist Group.

I wish to be contacted by email.

I also wish to sign up to the EIU (Economist Intelligence Unit) Perspectives newsletter.

The Economist Group is a global organisation and operates a strict privacy policy around the world. Please see our privacy policy here

Media partnership and press Request

By submitting this form we will send you updates associated with this event.

The Economist Events is a part of the Economist Group. We would love to keep you informed about other Economist events, newly-released content, our best subscription offers, and great new product offerings from The Economist Group.

I wish to be contacted by email.

I also wish to sign up to the EIU (Economist Intelligence Unit) Perspectives newsletter.

The Economist Group is a global organisation and operates a strict privacy policy around the world. Please see our privacy policy here